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Chapter 1 
Introduction and outline of the thesis 
1.1 History 
The history of growth hormone (GH) starts in 1921 when Evans and Long demonstrated the 
presence of a growth-promoting substance in the anterior pituitary'. Human growth hormone 
was first isolated in 1956 by Li and Papkoff2. In 1971 the growth hormone molecule was 
demonstrated to exist of one single chain of 191 amino acids including two disulphide 
bridges3-4 
Raben demonstrated beneficial effects of GH on growth in growth hormone deficient children 
in 19585. Since about 1970 GH is important in the treatment of stunted growth due to severe 
growth hormone deficiency in children. Although other physiological effects of growth 
hormone were observed during treatment of children with growth hormone deficiency, the 
most important clinical effect was skeletal growth. Due to the fact that growth hormone was 
derived from human pituitaries its availability was limited. This scarcity made GH expensive 
and only available in very small quantities not suitable for experimentation. Therefore, 
treatment of adults was not undertaken, despite the fact that adult patients with growth 
hormone deficiency suffered from both psychosocial and physical strain. Treatment of the 
first adult with growth hormone deficiency due to panhypopituitarism occurred in 1962, with 
a beneficial effect6. 
In 1979 biosynthetics of human growth hormone were described by Goeddel et al7. From than 
on unlimited amounts of natural growth hormone became available, without the so feared 
pituitary contaminants (Creutzfeld-Jacob syndrome). Around 1985, growth hormone also 
became available for the treatment of disorders other than severe growth hormone deficiency 
in children. Soon experimental GH treatment of patients with stunted growth, for example due 
to renal insufficiency, Turner and Prader-Willi syndrome, idiopathic short stature, skeletal 
dysplasia, and intrauterine growth retardation as well as adults with growth hormone 
deficiency started. From 1989 on the effects of GH treatment in growth hormone deficient 
adults were studied with an increased intensity. Other indications are studied also, for 
example the effects in frail elderly and on the recovery after hip fracture or bum. Further GH 
is - unjustified - used in sports for increasing performance of athletes. 
The diagnosis of growth hormone deficiency in adults proved to be difficult. For children the 
'golden standards' are growth velocity and height with an additional 24-hour growth hormone 
profile and provocation test(s). For obvious reasons growth velocity and height could not be 
used in adults while the 24-hour growth hormone profile appeared not usable, leaving 
provocation test(s) the only test(s) applicable in adults. The accuracy of the most used tests 
will be discussed in the introduction. 
Whereas the effects of short-term substitution of GH in GH deficient adults are fairly known, 
the long-term effects as reported in literature are scarse. Furthermore little attention has been 
paid to the gender difference in GH secretion and the consequences of GH treatment. 
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1.2 Modulation of GH secretion 
1.2.1 Growth hormone pathway 
The growth hormone pathway compromises a series of independent genes, whose products 
are required for normal function. The GH pathway genes include ligands (GH, IGF-I), 
transcription factors (PITI, PROPl), agonists (GHRH), antagonists (somatostatin, GHIF) and 
receptors (GHRH-receptor (GHRHR) and GH-receptor (GHR)). The effective and regulated 
expression of the GH pathway is essential for homeostasis of carbohydrate, protein, and fat 
metabolism8 (see figure 1). 
1.2.2 Growth hormone releasing hormone, somatostatin and ghrelin 
Both growth hormone releasing hormone and somatostatin are released at the median 
eminence into the hypophysal portal circulation. GHRH is synthesised in the arcuate nucleus 
and the ventromedial nucleus, whereas somatostatin is produced in the periventricular and 
paraventricular nuclei. GHRH stimulates both synthesis and release of growth hormone; 
somatostatin only inhibits the GH release leaving the synthesis unchanged910". GHRH is 
involved in the initiation of a GH pulse while somatostatin modulates the pulse amplitude9, l 2. 
Pharmacological studies showed that activation of a2-adrenergic receptors and muscarinic 
receptors stimulate GH secretion13. a2-Adrenergic agonists such as Clonidine stimulate the 
GH release, whereas a a2-adrenergic antagonist such as yohimbine can block GH release14. 
Dopaminergic agonists stimulate spontaneous GH release and enhance the GH response to 
GHRH in normal subjects13. Other neurotransmitters that modulate GH release such as 
serotonin and γ-aminobutyric acid and histamine can stimulate GH release via type 2 
somatostatin receptors or inhibit its release via the same receptor. 
A number of physiologic factors such as insulin induced hypoglycaemia, exercise and other 
forms of stress, stimulate GH probably by the c^-adrenergic pathway because this GH release 
can be blocked by the administration of phentolamide15. 
IGF-I and Π have a negative feed back regulation on growth hormone16. In cultured rat 
pituitary cells IGF-I decreases GH secretion and mRNA levels17. 
Ghrelin is a natural ligand of the GH secretagogue (GHS) receptor. Ghrelin strongly 
stimulates GH secretion in animals and humans showing synergistical effects with GHRH but 
no interaction with synthetic GHS. The activity of Ghrelin is not fully specific for GH as it 
also stimulates lactotrophic and corticothropic secretion in humans18. 
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Figure 1 Growth hormone release pathway 
1.2.3 Growth hormone and the signal transduction 
The actions of GH are mediated by the binding of GH to the transmembrane GHR, the first 
member of the type 1 cytokine receptor family. Most cells present the GHR to their surface. 
The GHR utilises the JAK-STAT signal transduction pathway19. The activated GHR 
associates with JAK2, which phosphorylates STATs-1, -3, 5a, and 5β on tyrosines19. After 
phosphorylation the STATs are translocated to the cell nucleus20,21. 
GHR also induces tyrosine phosphorylation of the insulin receptor substrate (1RS) proteins. 
The 1RS proteins are docking proteins that directly integrate signals from the IGF and insulin 
receptors to various down stream signalling pathways22. 
GH has also been shown to induce increased influx of extracellular calcium via the plasma 
membrane voltage-dependent L-type calcium channels23. 
1.3 Growth hormone deficiency in children 
1.3.1 Growth hormone deficiency in children 
Estimates of the frequency of GH deficiency in children range from 1 in 4000 to 1 in 10000 in 
various studies ' 5 . In children several causes of growth hormone deficiency can be 
identified. Most common is idiopathic (partial) GH deficiency (65% of the cases), followed 
by organic and iatrogenic causes (22%) and by craniospinal irradiation (11%)26. 
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1.3.2 Idiopathic growth hormone deficiency in children 
Idiopathic isolated growth hormone deficiency in children has been estimated to occur with a 
frequency of about 1 in 400027 A child with growth hormone deficiency must be necessarily 
short, although shortness is a relative condition and not an absolute one Growth hormone 
deficiency is charactensed by a low growth velocity Due to the lack of the lipolytic effects of 
growth hormone, children suffering from growth hormone deficiency appear to be fat 
1.3.3 Genetic causes of growth hormone deficiency 
Defects in the growth hormone pathway share common clinical features such as short stature 
and metabolic changes (information about genetic disorders can be found at 
http //www3 ncbi nlm nih gov/Omimfl 
1.3.4 Turner syndrome 
Patients with Turner syndrome28 are bom rather short, have a growth velocity within the 
lower part of the normal range, which results in a short stature Other characteristics of this 
syndrome are gonadal dysgenesis, webbing of the neck, low postenor hairline and increased 
angle of the elbow29 Growth hormone replacement was started in the early 1970s with a low 
dose and a low frequency of GH, results were then somewhat disappointing (increase in final 
height of 2 or 3 cm)30 The most recent publication, using an optimal scheme of GH and 
estrogens, indicates that the final height in patients with Turner syndrome is increased with 
most patients reaching normal adult height31 
1.3.5 Noonan Syndrome 
This syndrome occurs in both boys and girls and is different from Turner syndrome in the 
way that these patients have normal karyotypes Mean final height for men is 161 cm and 151 
cm for women 2 
The first studies published showed that after treatment with GH the height SDS and growth 
rate increased33 No data on final height after GH treatment are available 
1.3.6 Intra-uterine growth retardation or short for gestational age 
Some studies evaluating the effect of patients with intra-utenne growth retardation have been 
published Many of these patients showed abnormalities in GH secretion and/or 
utilisation3435, although no overt growth hormone deficiency could be demonstrated in the 
majority of the patients Studies show an increase in growth velocity after the administration 
of GH in a dose of 0 13-0 39 mg/m2/day but this increase is accompanied by an acceleration 
of bone age in these patients36 Preliminary data suggested a positive influence of growth 
hormone on the final height of those patients who suffered from intra-utenne growth 
retardation without a catch-up growth within the first two years of life 
1.3.7 Organic and iatrogenic causes of GH deficiency 
In children (and adults) GHD can be caused by a diversity of disorders, among which trauma 
(head, perinatal events), infections (meningitis, granuloma), neoplasms (craniopharyngioma, 
germinoma, histocytosis), irradiation, and others Further GHD can be part of various 
dismorphic syndromes such as septo-optic dysplasia, cleft lip and/or palate or empty sella 
syndrome 
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1.4 Growth hormone deficiency in adults 
1.4.1 History 
Although, as early as 1963 Falkheden treated the first adult patient with GH deficiency with 
growth hormone3 , the syndrome of growth hormone deficiency in adults has been recognised 
as a clinical entity only in 199238. Due to the fact that almost all patients had a growth 
hormone deficiency as part of (pan) hypopituitarism, it is difficult to precisely define adult 
growth hormone deficiency syndrome. 
In 1989 treatment started with a standard dose of 0.08 mg/kg/week, however, due to side 
effects caused by fluid retention the regimen was adjusted. The then advocated GH regime 
starts with an initial dose of 0.04 mg/kg/day for about one month followed by a maintenance 
dose of 0.08 mg/kg/week. This regimen was used till the end of the nineteen nineties. From 
then on a dose titration based on the IGF-I levels with a low starting dose (0.15 mg/day) 
became the treatment of choice. 
1.4.2 Causes of growth hormone deficiency in adults 
In most adult patients with GH deficiency the cause is known. In only 13% of the patients the 
aetiology is idiopathic. Most frequently reported causes are pituitary adenomas (52%) and 
craniopharyngioma (13%)(table 1). 
Table 1 Causes of GH deficiency (pituitary deficiency)(combined data of 
references 39'4φ) 
Causes of GH deficiency (pituitary deficiency) 
Pituitary adenoma (all) 
Non-secreting pituitary adenoma 
Prolactinoma 
ACTH secreting 
GH secreting 
GnRH secreting 
Thyrotropin secreting 
Other pituitary tumours 
Craniopharyngioma 
Cerebral tumour (other) 
Idiopathic 
Other 
Number (%) 
2610(51.7%) 
1144(22.6%) 
438 (8.7%) 
290 (5.7%) 
77(1.5%) 
16 (0.4%) 
8 (0.2%) 
177 (3.5%) 
677 (13.4%) 
213 (4.2%) 
646(12.8%) 
732(14.5%) 
1.4.3 Childhood onset (CO) versus adulthood onset (AO) GH deficiency 
In the population as a whole differentiation between patients with childhood onset of GH 
deficiency and patients with adult onset GH deficiency is made by various authors. Childhood 
onset GH deficient patients are defined as those who received GH in order to accelerate a 
stunted growth, whereas adult onset patients are those who acquire GH deficiency during 
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adult (adolescent) life. Besides differences in anthropometry (Table 2) differences in the cause 
of GHD can be identified. 
Table 2 Anthropometric differences between CO and AO growth hormone 
deficiency40 
Parameter 
Age (years) 
Height (cm) 
Weight (kg) 
BMI (kg/m2) 
Childhood onset 
28.9±9.3 
163.5±9.5 
71.5±19.4 
26.6±6.3 
Adulthood onset 
49.4±12.6 
169.3±7.7 
83.2±16.4 
29.0±5.5 
For patients with childhood onset GH deficiency most frequently reported causes are 
idiopathic GH deficiency and craniopharyngioma (together 62.8% of the population), while in 
adult onset GH deficiency patients pituitary adenomas are reported in 51.7% of the patients. 
Another important difference is that due to the fact that the current treatment in children can 
be considered insufficient - the treatment is stopped at the moment the patient reaches (near) 
adult height - not all body systems are fully developed which can especially be seen in a 
considerably lower peak bone mass in patients with childhood onset. 
Although the observed differences may have some clinical value at this point of time, 
it is to be expected that in the (near) future these differences loose their clinical relevance. The 
differences in age will, partly, be resolved within 2 or 3 decades. Further the treatment of 
children with GH deficiency will be continued till far in adulthood. No information on age 
comparable groups with either AO or CO are available at the time, but it is to be expected that 
the differences now observed between CO and AO patients will be smaller if not resolved in 
the future. Recently data are published supporting this idea41. 
Only the various causes of GHD will not change in time. Therefore, it is probably more 
relevant to divide the population of GHD patients according to the cause of GHD, than to the 
now used division in CO and AO. In our observation the extent of the cerebral surgery gives 
an indication of the success of GH replacement. Patients with major operations involving 
more than the pituitary gland alone, with visual deficits, epilepsy or other signs appear to have 
less to no benefit from GH replacement, whereas patients with discrete pituitary pathology 
benefit most from GH replacement. 
1.4.4 Growth hormone deficiency syndrome in adults 
The syndrome of growth hormone deficiency includes, among others, deteriorated quality of 
life, changes in body composition, reduced strength and exercise capacity, reduced bone 
mineral content, changes in cardiac function, renal perfusion, immune system and metabolic 
homeostasis. 
1.4.4.1 Psychological well being 
Compared to normal controls, patients with untreated growth hormone deficiency have a 
reduced QoL42'43,44,45. Studies comparing growth hormone deficient adults with matched 
controls showed that patients with growth hormone deficiency were more psychological 
labile, more socially isolated, less energetic (including an increased sleep requirement), less 
assertive and less vital46,47. Further they had poorer health, less self-control, and they 
experienced more anxiety. Patients with growth hormone deficiency have problems in their 
sexual relationships. 
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1442 Body composition 
In the first studies addressing the body composition in adults patients with growth hormone 
deficiency Binnerts et al48, and de Boer et al 4 9 found that impedance measured by body 
impedance analysis (ΒΙΑ) was statistically significantly higher in patients with GHD than in a 
matched control group Later publications showed that in patients with GHD fat free mass 
(FFM) is decreased by about 10% A gender difference can be observed with men having 
about 2-6% less FFM as compared to healthy controls and women 5% to 11% 
Table 3 Fat free mass or lean body mass (kg; mean ±SEM) 
Author 
Binnerts et al ** 
Snel et al50 
Method 
Deutenum 
ΒΙΑ Lu 
ΒΙΑ De 
BIARJL 
ΒΙΑ Lu 
Densitometry 
GHD patients 
Males Females 
46 6±3 9 
45 4±3 7* 
45 3±3 2* 
63 7±1 7 
60 0±15 
57 0±16 
45 9±1 8 
44 4±14 
40 0±19 
Controls 
Maies Females 
52 4±2 3 
56 5±2 3 
54 1±2 1 
65 1±23 
63 0±2 2 
60 5±2 5 
47 6±2 1 
48 1±4 
44 3±2 0 
* slatistically significantly different (GHD versus controls) p<0 05, De = Deurenberg, 
Lu = Lukaski, RJL = RJL systems 
Fat mass (FM) expressed in kg appears 30%-40% higher in patients with GHD than in 
controls Again a gender difference can be identified, men having about 30% more fat than 
their controls and women about 40% 
Table 4 Fat mass (kg; mean±SEM) 
Author 
Binnerts et al4" 
Rosén et al31 
Snel et al5U 
Method 
Densitometry 
ΒΙΑ Lu 
ΒΙΑ De 
Total potassium 
BIARJL 
ΒΙΑ Lu 
Densitometry 
GHD patients 
Maies Females 
26 2±2 3** 
27 3±2 4*** 
27 4±2 8** 
23 2±1 3*** 
180±10 
21 8±13 
24 5±15 
24 9±1 6*** 
21 4±16 
22 8±2 3 
28 6±1 7 
Controls 
Maies Females 
18 4±1 8 
14 2±17 
16 6±18 
20 8±1 0 
12 6±13 
14 7±2 1 
17 2±2 2 
21 6±1 8 
13 9±1 1 
13 4±1 5 
17 3±17 
** statistically significantly different (GHD versus controls) p<0 01, *** p<0 001, De = 
Deurenberg, Lu = Lukaski 
Percentage body fat (%BF) is increased in patients with GHD with 30-50% Compared to 
normal controls, women have 50% more fat against men "only" 40 The difference between 
both genders is less pronounced than for the FFM and FM 
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Table 5 Percentage fat mass (mean±SEM) 
Author 
Binnerts et al4" 
De Boer et al4' 
Snel et al5" 
Van Marken 
Lichtenbelt et al54 
Boaeus et al52 
Method 
Densitometry 
ΒΙΑ Lu 
ΒΙΑ De 
ΒΙΑ 
Skin folds 
BIARJL 
ΒΙΑ Lu 
Densitometry 
Deuterium dillution 
DEXA 
Total potassium 
TBW tritium dilution 
ΒΙΑ 
GHD patients 
Males Females 
36?+? λ*** 
37.6±2.2*** 
37.1±2.3*** 
32.4±6.2*** 
21.8±3.6* 
21.9±0.8 
26.3±1.0 
29.7±1.3 
27.3 
31.2±1.0 
32.8±26 
41.6±0.7 
39.4 
23.9 
23.5 
24.2 
20.4 
Controls 
Males Females 
25.3±1.6 
19.3±1.6 
22.6±1.5 
16.3±3.3 
15.4±4.0 
16.0±1.3 
18.7±2.2 
21.9±2.4 
19.3 
22.5±1.4 
21.7±2.2 
27.9±2.2 
32.6 
(17.5) 
(17.5) 
(17.5) 
(17.5) 
* statistically significantly different (GHD versus controls) p<0.05, *** p<0.001, De = 
Deurenberg, Lu = Lukaski; RJL = RJL-systems 
Patients with GHD have less total body water (TBW) as compared to healthy controls, men 
having about 5% less and women about 10% less TBW as compared to healthy controls. 
Table 6 TBW (L; mean±SEM) 
Author 
Snel et al3" 
Rosén et al51 
Van Marken 
Lichtenbelt et al54 
Method 
BIARJL 
ΒΙΑ Kush 
Densitometry 
Total potassium 
Deuterium dilution 
ΒΙΑ 
GHD patients 
Males 
45.0±1.0 
44.0±1.0 
41.8±11 
45.2±0.9*** 
36.74 
35.22 
Females 
33.0±1.0 
31.8±1.0 
29.3±1.4 
29.9±0.9*** 
30.64 
29.16 
Controls 
Males 
46.8±1.3 
45.0±1.3 
44.3±1.9 
(47.6±0.7) 
41.74 
39.86 
Females 
36.9±1.7 
35.0±1.6 
32.4±1.5 
(33.1±0.7) 
34.33 
33.02 
*** statistically significantly different (compared to the predicted value) p<0.001, Kush=Kushner, 
RJL = RJL-systems, (..)=predicted value 
Extra cellular water (ECW) is decreased in patients with GHD. The decrease is about 5% in 
males and 15% in female. 
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Table 7 ECW (L; mean±SEM) 
Author 
Snel et al5" 
Rosén et al51 
M0lleretal5J 
Van Marken 
Lichtenbelt et al54 
Method 
Bromide dilution 
Total potassium 
Bromide dilution 
Bromide dilution 
GHD patients 
Males 
18.3±0.6 
20.1±0.5*** 
Females 
13.3±0.7 
14.1±0.6*** 
i* 
14.70* 13.28* 
Controls 
Males 
18.8±0.7 
22.5±0.4 
Females 
15.6±0.9 
16.9+0.4 
15.64 13.84 
* statistically significantly different (GHD versus controls) p<0.05,, *** p<0.001, 
In patients with GH deficiency plasma volume is statistically significantly reduced compared 
to healthy subjects53. The Extra Cellular Water/ Intra Cellular Water (ECW/ICW) ratio in 
patients with GHD is increased with both the ECW and more so ICW decreased in patients 
with GHD as compared to healthy controls54. The measurement of body composition in 
patients with GHD has some pitfalls. Total Body Potassium (TBK) in these patients can be 
inaccurate due to the reduced potassium concentration found in these patients55. 
1.4.4.3 Muscle mass and strength 
Compared to healthy controls patients with GHD have a reduced quadriceps muscle mass5 . 
The decrease in muscle volume is accompanied by a reduced isometric and isokinetic muscle 
strength56-57. Using cycle ergometry, values for maximum oxygen uptake were reduced being 
on average 72-84% of those predicted for age, sex, and height5 . 
1.4.4.4 Metabolism 
Reduced whole body resting energy expenditure has been demonstrated in patients with 
growth hormone deficiency. Studies using stable isotope tracer techniques showed that in 
patients with growth hormone deficiency a reduced protein flux and synthesis can be 
demonstrated59,60. 
1.4.4.5 Carbohydrate metabolism 
Adults with GH deficiency have normal overnight glucose levels and normal overall glucose 
turnover. In the absence of GH, insulin secretion is aberrant which may be associated with 
impaired glucose tolerance. The lack of GH is associated with normal insulin sensitivity but 
reduced hvpoglycaemic responsiveness, probably due to a reduced supply of gluconeogenic 
substrates '. The increased central adiposity combined with the hyperinsulinaemia as can be 
found in growth hormone deficient adults is suggestive for an increased insulin resistance. 
The insulin resistance was demonstrated using clamp technique and Bergman's minimal 
model62,63. Some evidence suggested that the hepatic glycogen stores are reduced64. In adult 
patients with GHD a glucose intolerance is described65. 
1.4.4.6 Cardiovascular system 
Analysis of over 300 hypopituitary patients over a period of 30 years showed an increased 
mortality of about lOOÌi)66, which was mainly due to an increased risk of premature death 
from cardiovascular disease. 
GHD adolescents, regardless of whether or not they received GH replacement, do not seem to 
show alterations in cardiac mass and function or early atherosclerotic changes67. 
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The mechanisms responsible for the increased mortality in these patients remains poorly 
understood. It was suggested that the increased mortality might be associated with growth 
hormone deficiency. Increased intima-medial thickening, intimai plaque formation, impaired 
endothelium-dependent vasodilatation and reduced arterial compliance probably play a role in 
the increased mortality68·69·70·69·71 
Studies investigating cardiac dimensions and performance have demonstrated reduced left 
ventricular mass and impaired cardiac systolic function in adults with growth hormone 
deficiency as compared to healthy controls 2·7 3·7 4. 
j75,76 
1.4.4.7 Lipid profile 
In adult patients with hypopituitarism hyperlipaemia has been described'3'0. Some studies 
indicate enhanced levels of total cholesterol, low-density lipoprotein cholesterol, apo Β and 
serum triglycerides. 
Table 8 Lipoprotein pattern in GHD adults 
study 
Libber et al.77 
Russell-Jones et al78 
Wüster et al'9 
Cuneo et al"" 
Rosén et al81 
de Boer et al"2 
Davies et al" 
Stathopoulou et al84 
Ν 
36 
18 
122 
24 
104 
64 
48 
14 
age 
18^6 
46.8 
18-80 
18-52 
18-73 
19-39 
45.9 
49.3 
total 
cholesterol 
Τ 
<-> 
Τ 
τ 
<-» 
τ 
«-» 
<-> 
LDL 
cholesterol 
î 
<-> 
ND 
Τ 
ND 
î 
<-> 
<-> 
HDL 
cholesterol 
ND 
<-> 
ND 
i 
i 
<-» 
<-» 
<-» 
apo Β 
Τ 
<-> 
ND 
Τ 
ND 
Τ 
<-> 
o 
serum 
triglyceride 
<-» 
<-> 
î 
î 
Τ 
<-» 
<-> 
<-> 
Τ increased; i decreased; <-> not statistically different from control population; ND not 
determined 
Serum leptin reportedly is significantly higher in growth hormone deficient adults as 
compared to controls ' . The increase was more marked in obese patients compared to obese 
controls than in lean patients compared to lean controls85. Women in either group had 
significantly higher leptin concentrations than men85,86. 
1.4.4.8 Bone 
Bone mineral density is reduced in patients with growth hormone deficiency87'88,89'90. For 
patients with childhood onset the lower peak bone mass can only partly explain the low bone 
mass seen in adult patients with childhood onset GHD. 
Growth hormone deficient adults (both CO and AO) have an increased fracture rate91 
(total fracture incidence 24.1% in patients against 11.8% in normal controls). 
1.4.4.9 Haematological and Immunologic system 
Erythropoiesis is impaired in patients with GH deficiency92. 
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The fibrinolytic system in GH deficiency is characterised by an increased plasminogen 
activator inhibitor-1 (endothelial inhibitor) and high fibrinogen93,94. Levels of tissue 
plasminogen activator were not different from the control group while plasminogen activator 
inhibitor activity is increased93,94. 
Although GH has some distinct effect on the immunologic system, none had any clinical 
relevance95. The scanty literature available on immunology indicates a reduced non killer cell 
number and activity, a reduced antibody synthesis, and a defective antibody- and cell-
mediated immunity95,96,97. Further, patients with GH deficiency have elevated plasma 
concentrations of tumour necrosing factor alpha and interleukin-6 and increased adhesiveness 
of blood monocytes.98 
1.4.4.10 Other 
Patients with GH deficiency have reduction in FEVi, TLC (total lung capacity) and 
pyp99,100,101 
Decreased systemic nitric oxide (NO) production has been reported in adult GH deficient 
patients102. 
GH plays a role in testicular function. Isolated GH deficiency is associated with a poor 
response to exogenous hCG administration103. 
Growth hormone nor IGF-I play a significant role in the regulation of sebum excretion in 
men 
Sweating is decreased in children with a growth hormone deficiency105 
1.4.5 Diagnosis of adult GHD 
1.4.5.1 Current consensus on diagnosis 
The most accepted guideline for the diagnosis of GH deficiency is the 1998 "Consensus 
guideline for the diagnosis and treatment of adults with growth hormone deficiency: 
Summary statement of the growth hormone research society workshop on adults growth 
hormone deficiency"106. This guideline is adapted by the Japanese, Australian and American 
(FDA) authorities. The European Medicines Evaluation Agency (EMEA) accepted a slightly 
differentiated guideline (see Chapter 6). 
The growth hormone research society (GRS) guideline advises that only patients with 
suspicion for GHD are subjected to a provocation test. Suspicion is aroused when patients are 
known with pituitary-hypothalamic disease, have a defect of at least one pituitary axis or have 
a low IGF-I level for no obvious reason, have been treated with growth hormone in childhood 
or show the clinical syndrome of a growth hormone deficiency. In case suspicion is aroused 
an adequate provocation test should be performed. In the GRS guideline the ITT is advocated 
as golden standard with arginine and arginine plus GHRH as acceptable alternatives. The 
Clonidine provocation test is obsolete in the diagnosis of growth hormone deficiency in adults. 
Further the GRS guideline advocates to use a cut-off of 3μg/ml (10 lU/ml). 
The European Commity on Proprietary Medicinal Products (CPMP) recommendations on 
diagnosis and treatment of adults with growth hormone deficiency (Chapter 6) are somewhat 
different. No preference for a provocation test is given (the Clonidine test, however, is not 
advised), while the cut-off is considered laboratory and test specific. Further the European 
guideline gives clear direction for the diagnosis in adults previously treated with a partial 
GHD. 
1.4.5.2 IGF-I 
Although IGF-I is low in almost all patients with GH deficiency107 IGF-I is not usable for 
diagnosis per se. Too many other clinical conditions are associated with a decreased IGF-I 
17 
level, for example malnutrition/malabsorption, impaired liver function, extreme stress, 
impaired kidney function, further changes in prolactin, insulin, thyroid hormones, 
glucocorticosteroids and androgens were associated with low IGF-I levels. Notwithstanding 
this, IGF-I can be used as a screening method. Youngsters below 30 year of age with low 
IGF-I (<2 SDS) are suspect for growth hormone deficiency, assuming that no other cause can 
be identified on beforehand108. Elderly (>40 years) can be excluded to have GH-deficiency 
when IGF-I exceeds 1.5 SDS. (see Chapter 2). 
1.4.5.3 IGF binding proteins (IGFBP's) 
IGFBP-3 is quantitatively the most important IGF-I binding protein. After binding of either 
IGF-I or IGF-Π it binds another protein, acid-labile subunit (ALS), to constitute a larger 
complex. IGFBP-3 is directly regulated by GH and is thought to be usable as a surrogate 
marker for GH activity. IGFBP-3, however, is influenced by other variables than GH, for 
example malnutrition/malabsorption, impaired liver function, extreme stress, impaired kidney 
function. Furthermore, prolactin, insulin, thyroid hormones, glucocorticosteroids and 
androgens increase the IGFBP-3, whereas oestrogen decreases IGFBP-3. IGFBP-3 is more 
usable as a screening for patients with a possible GH deficiency, but does not contribute more 
to the diagnosis than IGF-I. 
In children IGFBP-3 concentration showed a poor sensitivity for the diagnosis of GH 
deficiency109. However, specificity of this measurement is about 90% in children above the 
age of 5 years and about 94% in children below the age of 5 years. In their study Cianfarani et 
al109 used the 10% percentile as cut off for the diagnosis growth hormone deficiency. The 
Clonidine test was used as a "golden" standard. 
1.4.5.4 24 hours growth hormone profile 
In patients with growth hormone deficiency the GH production was significantly less than 
seen in healthy volunteers as were the pulse frequency, amplitude, height and percentage GH 
secreted in peaks110. Because of the patient burden and the economic and logistic troubles this 
test is the less used in the diagnosis of adulthood GHD, although it is the only test available 
enabling measurement of the actual GH production. 
1.4.5.5 GH measurement in urine 
In patients suffering from acromegaly the urinary growth hormone excretion over 24 hour 
gives more direct information about the GH status than IGF-I1". In children with isolated 
GHD the night-time GH secretion is decreased when compared with healthy children (sex and 
age matched) while the day-time GH secretion is not different between the children with 
GHD or the healthy controls"2. The use of urinary GH concentration for the diagnosis of adult 
GHD is at best unclear at this moment. 
1.4.5.6 Provocation tests 
For the diagnosis of growth hormone deficiency in adults a diversity of provocation tests is 
available. This is not because GH-deficiency is an easy diagnosis, but rather reflects the 
variable results obtained with all available provocation tests. The most used test is the ΠΤ, its 
limited usefulness in patients with multiple pituitary deficiencies is known"3 '"4. Other 
disadvantages of the ΓΓΓ are the fact that the test is unpleasant for the patient, and is contra-
indicated in the presence of cardiovascular disease or seizures. Acceptable alternatives are the 
arginine test and the arginine-GHRH test"5. Other provocation tests used are the GHRH, 
glucagon, Clonidine and pyridostigmine tests. The reliability of these tests for the diagnosis 
GHD in adults is under discussion107 except for the Clonidine test with is considered 
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unreliable115. All mentioned tests, except the GHRH test, test the whole GH pathway by 
stimulating the hypothalamus. 
Recently a lot of combination tests (for example pyridostigmine + GHRH107, Clonidine + 
GHRH107, GHRH + Growth Hormone Releasing Protein-2116, GHRH + a-
glycerylphosphorylcholine117) have been developed, most showing promising results, 
although their accuracy remains to be demonstrated, yet. One of the greatest advantages of the 
combination tests is the high stress they induce on the GH-IGF-I axis with high GH peaks 
after provocation. The major drawback is the fact that they only test the pituitary function 
circumvening the hypothalamic input. 
1.4.6 Treatment of adults with GH deficiency 
1.4.6.1 Growth hormone dose 
In 1986 the first paper about systematic treatment with GH of GHD adults was published118. 
In the first studies the improvement of the psychological well being was the most important 
finding. 
In the first studies the dose administered was 0.08 mg/kg/week divided in daily doses. Due to 
side effects later studies used a starting dose of 0.04 mg/kg/week followed by a dose of 0.08 
mg/kg/week. 
The latest development shows that a starting dose of about 0.33 mg/day followed by a 
titration dose gives the least side effects119120'1 '. 
1.4.7 Effects of GH treatment in GH deficient adults 
Growth hormone replacement reportedly exerts a diversity of effects in the growth hormone 
deficient adult. Most marked are the changes in well being and the increase in body 
composition. Other important changes are the improved lipid profile and the increase in bone 
mineral density. Growth hormone exhibits effects on carbohydrate metabolism, sweating, 
increased hair growth (primary and secondary), muscle strength, sex drive and the immune 
system. Further it is known that growth hormone modulates efficacy of thyroid and 
corticosteroid hormones. 
1.4.7.1 Psychological and social aspects 
The first study on the quality of live (QoL) in adult patients reporting a positive effect was 
published in 1986118. Due to the limited number of patients none of the improvements reached 
statistical significance. Further studies evaluating the effects of (fixed dose) GH replacement 
(0.01 mg/kg/week) on QoL resulted in conflicting data. Some studies showed a definite 
positive effect122, others a limited positive effect1 3·124125·126·127
 o r n o statistical significant 
effect et all128129. In studies using a variable GH dose (treatment goal IGF-I within 2 SD 
scores of the age-corrected mean) positive effects on the quality of life were reported130. 
After all it can be assumed that GH substitution has a positive effect on the quality of life in 
most patients. In case no positive effect on well being was seen after about one year, 
continuation of the treatment can be questioned unless other important improvements are seen 
or experienced. 
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1.4.7.2 Metabolic effects and body composition 
1.4.7.2.1 Effects on total body water (TBW) and lean body mass (LBM) 
As most body composition measurements assume a constant relation between the parameters 
as LBM= 0.73*TBW, both parameters are discussed. 
Scrutinising the literature for the effects on total body water a biphasic response can be 
derived (see Figure 1). At first there is a rapid peak (increase/decrease) in TBW, which is not 
accompanied by a change in total body weight, suggesting a shift in body composition. Later, 
after about one year of treatment, again there is a rise in TBW now accompanied by an 
increase in body weight suggesting an increase in (muscle) tissue. 
In the first (water retaining) phase IGF-I mediated renotropic effects131,132 play a role. In the 
modulation of the renal function the Renin-Angiotensin-Aldosterone System (RAAS) 
probably plays a role as this system has been demonstrated to be influenced by GH in rats, 
healthy subjects and patients with GH deficiency133, 1 3 4 , 135. Another argument for the 
involvement of the RAAS system is the fact that RAAS blockade abolishes the effect of GH 
on fluid retention136. 
The second phase is probably induced by the anabolic effect of GH and IGF-I and is 
accompanied by an increase in body weight, this increase in TBW can be explained by the 
increase in cell mass (muscle tissue)(this thesis). 
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Figure 1 Changes (%) in TBW during GH treatment of GH deficient adults 
(meta-analysis from literature) 
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14 7 2 2 Effects on extra cellular volume (ECV) and plasma volume (PV) 
GH substitution in GH deficient patients increased the ECV Starting with a decreased ECV 
compared to healthy controls after 3 weeks of treatment no longer a difference with a control 
population could be demonstrated Although plasma volume increased in GH deficient 
adults during GH replacement after 3 weeks of treatment, the plasma volume still remained 
below that of healthy control subjects53 
1473 Effects on fat mass 
In man, GH is known to reduce adipose tissue mass1 3 8 1 3 9 Following GH treatment with a 
fixed dose of 0 01 mg/kg/day the growth hormone deficient adults lose 3-5 kg or 13-18% of 
their fat mass in the first 6 months of t rea tment 1 4 0 1 4 1 1 4 2 1 4 3 1 4 4 1 4 5 1 4 6 1 4 7 1 4 8 This decrease in fat 
mass was not the result of changes in energy expenditure or a changed exercise energy 
output149 After this initial decrease an increase in fat mass is seen, exceeding the baseline 
after about 5 years of treatment, but the fat mass remains below that of untreated patients after 
about seven years of treatment150151 
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Figure 2 Effects of GH treatment on fat mass in GH deficient adults (meta-analysis 
from literature) 
GH replacement titrated to a normal IGF-I showed a strong decrease in %FM, although no 
statistically significant decrease in fat mass (neither absolutely, nor in term of percentage) 
could be demonstrated (see Chapter 4 ) For men a decrease of 21% ± 11% was found after 3 
months of treatment The maximal decrease for women 8%±8% was found after 6 months of 
therapy During the 52 months treatment the mean change for women was never statistically 
significantly different from zero For men the difference was and remained statistically 
significantly different from zero from three months until 52 weeks (this thesis) 
Studies evaluating the effects of GH on the subcutaneous or visceral fat mass show that the 
decrease in visceral fat mass is more pronounced in the visceral area (men ±35%, women 
±30%) as compared to the subcutaneous area (±14% and ±9, respectively)152 
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1.4.7.4 Lipid metabolism 
Growth hormone substitution reportedly showed an increase in the release of free fatty 
acids153. In vitro studies show contradictory results GH treatment in GH deficient adults has 
been reported to increase the sensitivity of isolated adipocytes to catecholamines, whereas 
basic lipolysis was not affected154. In vitro studies however showed that incubation of 
adipocytes with GH for 4 hour had a direct stimulating effect on lipolysis155 
The concentration of HDL-cholesterol increased after 2-5 year treatment with GH, whereas 
the levels of total cholesterol and triglycerides did not change or decreased156151 Recently it 
was shown that GH counteracts an increased cholesterol synthesis induced by a high fat diet 
without affecting bile acid synthesis or sterol absorption 57. GH therapy did not have any 
major influence on the dietary effects on serum lipoprotein levels 
1.4.7.5 Muscle strength, exercise capacity and cardiac function 
The decrease in oxygen consumption and cardiac output in hypophysectomised patients was 
already demonstrated in 1963 by Falkenheden37 Blood pressure is not changed by GH 
replacement137,158. Heart rate slightly increased during GH replacement (form 67±3 beats to 
82±2 beats)137. Quadnceps muscle mass is increased after GH replacement therapy and 
consequently the muscle strength56 The increase in muscle strength is due to the increase in 
muscle mass as the intrinsic muscle strength is unchanged after initiation of GH 
replacement56. 
1.4.7.6 Cardiovascular risk factors 
Growth hormone replacement in GHD adults reverses early morphological and functional 
atherosclerotic changes in major artenes and, if maintained, may reduce vascular morbidity 
and mortality159-160. Further it is shown that after 1 year of growth hormone replacement in 
growth hormone deficient adults HDL-cholesterol is increased, while total cholesterol and 
LDL cholesterol is decreased160'161. Also left ventricular mass, left ventricular ejection 
fraction and exercise duration improve after GH replacement161. 
1 4.7.7 Bone metabolism 
Short term treatment with growth hormone162,1 3 increased serum calcium while serum PTH 
decreased steadily Effects on phosphate were small resulting in conflicting results with some 
studies reporting an increase , and others reporting no statistically significant different 
changes16 . Calcitriol increased within 4 days. Thereafter calcitnol concentration decreased 
and reached its baseline values after 10 days of treatment, free calcitnol followed the changes 
in the total calcitnol162. Plasma alkaline phosphatase, osteocalcin and procollagen 1 
carboxyterminal peptide increased after 6-42 months of GH treatment163164. No changes in 
PTH were observed163 Bone mineral content increased during 2-5 years of treatment with 5-
8% at the lumbar spine, 2-6% in the femoral neck, 4.9% in Ward's tnangle and 9 9% at the 
forearm151164·165·,66· 67. The effect of GH treatment on bone mineral density was more 
pronounced in men than in women165. 
1 4.78 Carbohydrate metabolism 
After a single dose of GH (0.06 or 0.12 mg) negligible changes in glucose concentrations 
were found 68. FFA concentration increased statistically significant after the highest dose of 
GH. Directly after the injection of GH, insulin decreased but increased thereafter. 
In a short term study (10 days) with high dose GH (0.067 mg/kg/day) glucose increased till 
day 6 of treatment and decreased thereafter returning to baseline after 8 days162. Insulin also 
increased dunng the first 7 days of treatment and decreased thereafter reaching it's baseline 
14 days after the start of treatment. No changes were seen in the glucagon levels 
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1.4.7.9 Thyroid and glucocorticosteroid hormones 
GH treatment increases extrathyroidal conversion of T4 to T3. Brixen et al reported an 
increase of serum T3 from 2.03±0.06 nmol/1 to 2.43±0.10 nmol/1 (p<0.001) during a short 
term study (10 days) with a high dose of GH (0.2 IU/kg/day)162. Concomitantly an increase in 
free T3 was seen. At the same time T4, free T4, Γ-Τ3 and TSH decreased. 
GH may decrease serum total Cortisol concentrations by decreasing circulating Cortisol 
binding globulin. Furthermore it may reduce bioavailability of Cortisol through an enhanced 
net conversion of Cortisol to Cortison 9. 
1.4.8 Safety 
Growth hormone treatment is associated with a number of adverse events. Most of these 
adverse events, such as pseudotumour cerebri, diabetes mellitus and slipped epiphysis, are 
reported in children only and seem to play no part in the adult treatment. Contrary to children 
the fluid retention causes the most adverse events in adults. 
Recurrence of pituitary tumours and the de novo malignancies cause great concern in adult 
patients (cf 1.4.8.2. and 1.4.8.3). 
Overall, growth hormone replacement in adults is fairly well tolerated with about 5% of the 
patients discontinuing the treatment for any reason1 . 
1.4.8.1 Most reported adverse events 
Most frequently reported adverse events occurring at the start of the treatment are related to 
fluid retention. About 30% of the patients reported myalgia and signs and symptoms related 
to a carpal tunnel syndrome and fatigue. About 10% of the patients treated with growth 
hormone reported adverse events originating from muscle or bone with arthralgia being the 
most common. Interestingly there is a gender difference with women more frequently 
reporting the mentioned side effects compared to men40. 
Most of the side effects can be "treated" by temporarily decreasing the dose. In the time of 3 
months these adverse events spontaneously disappear, possibly due to the weaning effect of 
GH on the fluid retention in the first year of treatment. 
1.4.8.2 Neoplasms (de novo) 
In the hypopituitary control and complications study (hypoCCS) and KIMS analysis 1% of 
the patients developed a de novo malignancy. Among the de novo malignancies were: 10 
patients with basal cell carcinoma, 5 mammary carcinoma, 5 colonic or rectal carcinoma, 4 
malignant melanoma, 3 bladder carcinoma, 3 prostate cancer, 3 non-Hodgkin lymphoma, 2 
CLL, 2 meningioma, 2 astrocytoma. Further isolated cases of planocellular carcinoma, renal 
cancer, oligodendroglioma, glioblastoma, pituitary carcinoma, lung cancer, AML, testis 
teratoma, leiomyosarcoma, vocal cord cancer and lentigo maligna were reported. 
Although in some recent studies IGF-I was found to be increased in patients with prostate 
cancer and pre-menopausal women with breast cancer, it is not likely that GH and/or IGF-I 
per se play a major part in the development of neoplasms. Reason for this belief is the 
suggestion that IGF-I concentrations are related to the increase in tissue volume (hyperplasia 
as well as neoplasm) and that in humans (acromegaly) as well as in animals with high IGF-I 
and/or GH levels the incidence of prostatic or breast cancer is not increased171. 
Comparing the incidence of the various malignancies with standardised incidence ratios'70, it 
can be concluded that the incidence of cranial tumours, malignant melanoma, bladder cancer 
and leukaemia seems to be increased in the patients treated with GH as compared to the 
normal population (only for cranial tumours the increase is statistically significant). For most 
of the remaining malignancies the incidence is unchanged by the GH treatment except for 
breast cancer for which the incidence seems to be decreased. 
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1.4.8.3 Tumour recurrence 
An increased incidence of certain malignancies (especially tumour recurrence) has been 
reported in hypopituitary adults but there is no evidence that this is associated with GH 
substitution1 9. 
Recurrence of the tumour occurred in about 1.5% of the patients40170. Recurrence of 
adenomas was about 4% for those patients known with adenomas. Recurrence of 
craniopharyngioma was about 2.5% of the patients previous known with craniopharyngioma. 
1.5 Outline of the thesis 
Diagnosing GH deficiency in adults still is cumbersome, despite the development of a 
diversity of provocations tests. In Chapter 2 we contributed to this discussion by highlighting 
the usefulness of measurement of IGF-I concentrations in diagnosing GH deficiency in adults. 
The similarity of IGF-I levels in healthy women and men, despite thrice higher GH 
production in the former, suggests lower GH responsivity in women than in men. In untreated 
GH deficient women IGF-I levels are even lower than in men and the therapeutic GH dose 
required to achieve optimal IGF-I levels higher, suggesting a role of sex steroids on GH 
requirement in GH deficient adults. In Chapter 3 we analysed this gender difference in GH 
requirement and scrutinised the role of estrogen and androgen substitution on IGF-I 
responsiveness to GH in GH deficient women and men, respectively. Assuming a gender 
difference in IGF-I responsiveness to GH, which may be sex steroid dependent, such 
difference could differentially influence the effect of GH therapy on body composition 
parameters (TBW, FFM and FM) in both sexes. 
In Chapter 4 attention was paid to possible gender differences in biological responses 
to GH in GH deficient women and men treated for 24 months. 
In short term studies a tremendous increase in TBW has been reported in the first 
months of GH substitution in GH deficient adults treated with a fixed, unadjusted dose GH. 
This increase is apparently evanescent as such huge fluid retention is no longer reported in 
studies lasting over one year. We therefore in Chapter 5 scrutinised the changes in TBW and 
%TB during 36 months of GH therapy in GH deficient women and men. Patients were treated 
with a titrated dose of GH and analysis comprised corrections for GH dose/kg body weight 
and the IGF-I level. 
As shown in Chapter 6 data from the Consensus of the GRS were the base for the 
CPMP guidelines. The deviations introduced in the CPMP guideline were mainly based on 
the data from the various chapters of this thesis. In practice the results as presented in this 
thesis have a relevant influence on the diagnosis and treatment of adults with GH deficiency. 
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ABSTRACT. Diagnosing growth hormone deficien­
cy in adults is difficult. Provocation tests are most 
commonly used for the diagnosis with the insulin-
induced hypoglycemia test nowadays considered 
as the "gold standard". The role of IGF-I concen­
trations in diagnosing growth hormone deficiency 
in adults is under discussion. In 58 adult patients 
with proven growth hormone deficiency, the sen­
sitivity and specificity of IGF-I concentrations in re­
lation to growth hormone deficiency were evalua­
ted. Reference values of plasma IGF-I were ob­
tained from 53 healthy volunteers. Using a calcula­
ted cut-off concentration of 15 nmol/l we were 
able to demonstrate that IGF-I concentration is a 
reliable screening method for growth hormone de-
INTRODUCTION 
There is no consensus about the most appropriate 
method of diagnosing growth hormone (GH) defi­
ciency in adults A wide vanety of diagnostic modali­
ties is used in order to ensure this deficiency Insulin-
induced hypoglycemia is the most widely used test 
and is considered as the "gold standard" (1) Ho­
wever, the insulin hypoglycemia test is difficult to per­
form because of the vanable insulin sensitivity of the 
individuals The test has many contraindications and 
may be dangerous because of the severe hypo­
glycemia that can occur, especially in patients who 
have multiple pituitary hormone deficiencies The­
refore, other provocation tests, like the argimn test, 
the Clonidine test or the propanolol-L-dopa test, are 
performed in order to diagnose growth hormone de­
ficiency In addition, a 24-hour growth hormone pro­
file is used in establishing the diagnosis Because of 
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fidency. Using this cut-off point in a patient popula­
tion younger than 40 years of age, sensitivity was 
90% and specificity 89%. For patients exceeding 
the age of 40 years, sensitivity, specificity and posi­
tive predictive value were rather low, but the neg­
ative predictive value was as high as 90%, indica­
ting that for patients over 40 years IGF-I concentra­
tions above 15 nmol/l exclude growth hormone 
deficiency. In summary, under the age of 40 years 
measuring plasma IGF-I provides an useful tool to 
diagnose growth hormone deficiency, whereas 
above 40 plasma IGF-I values exceeding 15 nmol/l 
virtually exclude growth hormone deficiency. 
(J. Endocrinol. Invest. 22: 446-450, 1999) 
»1999, Edrtnce Kurtis 
the limited sensitivity and specificity (1) of all these 
procedures, other diagnostic cntena such as the mul­
tiplicity of pituitary hormone deficiency, the concen­
traten of IGF-I and/or IGFBP-3, the ratio of IGF-I over 
IGFBP-3 and the acid labile subumt are used to es­
tablish an accurate diagnosis (1) The plasma IGF-I 
concentration can be of use in children to diagnose 
growth hormone deficiency because sensitivity and 
specificity are acceptable (2, 3) In adults the useful­
ness of the IGF-I concentration as a diagnostic modal­
ity is under debate Some studies demonstrate that 
the IGF-I concentration is a useful tool (4-6), whereas 
others found such a low sensitivity and/or low speci­
ficity that the measurement of IGF-I concentration per 
se is not suitable as a diagnostic tool for the asses­
sment of growth hormone deficiency (1, 7-9) To get 
more insight in the value of IGF-I measurement in the 
screening for growth hormone deficiency in adults, 
we assessed the IGF-I concentrations m a normal 
population and in growth hormone deficient patients 
EXPERIMENTAL SUBJECTS 
Fifty eight adult patients (mean age 37 2 years, 
range 20-73 years, 27 male and 31 female) with 
growth hormone deficiency were included Because 
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of the difficulties of the insulme-induced hypogly­
cemia and the tolerability of the patients, we used 
the argmin test for the diagnosis of growth hor­
mone deficiency. The arginin provocation test was 
only performed when a patient had signs and 
symptoms known to be related-to growth hormone 
deficiency and/or pituitary pathology. Growth hor­
mone deficiency was diagnosed when an arginin 
test revealed a peak growth hormone concentra­
tion below 1 0 m U / l ( 1 0 ) . 
Due to pituitary pathology, most patients had mul­
tiple pituitary deficiencies and received adequate 
hormonal replacement therapy except growth hor­
mone. The pituitary pathology consisted of cran­
iopharyngioma in 13 patients, unidentified pitu­
itary tumor in 10, idiopathic in 8, congenital 4, Cu-
shing's disease in 3, chromophobe adenoma in 3, 
epipharinx carcinoma, cerebral tumor, trauma, pro­
lactinoma, hypothalamic insufficiency each in 2 pa­
tients, and meningioma, germinoma, rhabdomyo­
sarcoma, empty sella, Sheehan's disease meningi­
tis and agenesis of the septum pellucidum each in 
one patient. Most patients had been treated sur­
gically with or without subsequent radiation; ther­
apy. Duration of growth hormone deficiency var­
ied from 1 to 36 years. In all patients non-pituitary 
illness or malnutrition were excluded. All patients 
signed an informed consent to the protocol which 
was approved by the University Hospital Ethical 
Committee. 
The control group consisted of 53 healthy volun­
teers (mean age 37.5 years; range 20-72 years; 27 
male and 26 female). 
Mean body mass index (BMI) for all patients was 
26.9±6.36 kg/m2 (mean±SD). For women the mean 
was 28.2±7.57 k g / m 2 and for men 2 5 . 3 ± 4 . 0 4 
kg/m2. In the control group, the mean overall BMI 
was 24.8±2.7 kg/m 2 with for women a mean of 
26.6±3.2 kg/m2 and for men a mean of 24.9±2.3 
kg/m2. The difference in mean BMI between pa­
tients and controls never reached a statistically si­
gnificance, although BMI in the patient group was 
higher that that of the controls in all analyses (total, 
men, women, decade). 
MATERIALS A N D METHODS 
IGF-I was determined by an in-house radioimmu­
noassay following acidification and silica C 18 ex­
traction of the plasma samples. The bound and free 
protein were separated using a solid phase second 
antibody coated cellulose suspension. The rabbit 
antiserum used in this assay showed negligible 
cross reactivity with IGF-II (<3%) The mtra-assay 
CV, expressed as the relative duplicate CV at con­
centrations between 5 and 50 nmol/l was 5.7%. The 
inter-assay CV was 9.4% at a level of 8.4 nmol/l, 
4 . 1 % at 29.8 nmol/l and 6.5% at an IGF-I concen­
tration of 41.7 nmol/l. The sensitivity of the assay 
was 7 pmol/l. 
Growth hormone was measured by direct radioim­
munoassay using the international W H O standard 
for human growth hormone 80/505. The inter-as­
say CV was 9.2, 7.8, 5.0% and 6.0% at GH concen­
trations of 4.7,10.6, 20.8 and 53.5 mE/l. The mtra-
assay CV, expressed as the relative duplicate vari­
ation of samples with a GH concentration between 
1.0 and 60 mE/l (n=40) was 5 . 1 % . 
In the healthy volunteers the relation between IGF-
I concentration and age was characterized by the 
formula: IGF -> 347.5*104 3 0 6 5*"!!« +16 (1) 
For our patients the relation between IGF-I concen­
tration and age for the patients with a growth hor­
mone deficiency is: IGF -> 0.0022*age+8.88 (2) 
In order to combine a 9 0 % sensitivity with a 9 0 % spe­
cificity we calculated the formula for the 10 t h percen­
tile of the normal population: K3F -» 5 1 7 * ΐ σ 0 1 5 5 3 9 * 
+13.9 (3) 
And combined this with the formula for the 9 0 * per­
centile of the patient population: IGF -> >0.02*age+ 
13.0 (4) 
The cut point of both functions is than: 51.7*10 
-0 1 5 S a g e + 1 3 . 9 = 0 . 0 2 * a g e + 1 3 . 0 ( 5 ) 
This gives an IGF-I value of 13.9 nmol/l and a value 
for age of 45 years, indicating that using the cut-
o Controls · GHD 
20 30 40 50 60 70 80 
Age (yr») 
Fig 1 - Plasma IGF-I concentrations during life span in controls 
and patients with GHD 
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Table 1 - Mean plasma IOF-1 concentrations and 95% Cl for different age groups 
Age group Normal population 
no mean IGF-I 95% CI 
(nmol/l) 
GHD 
mean IGF-I 
(mnol/l) 
95% CI 
p-value 
>20-30yeare 
>30-40 veare 
>40-50 years 
>50-60 years 
>60-73 years 
9 
9 
11 
17 
7 
26 7 
19.8 
177 
1 5 9 
1 4 8 
21 8-31 5 
16.4-23 3 
158-197 
13 5-18 2 
12 1-175 
17 
14 
16 
8 
3 
1 0 5 
7 3 
9 1 
1 0 6 
11 1 
7.9-13.1 
4 8-9 8 
6.9-114 
7 5-13 7 
7.6-14 6 
<OO01 
<0 001 
<0 001 
<0 01 
NS 
NS-not statistically significant 
off of 13.9 nmol/l sensitivity and specificity for pa­
tients below the age of 45 of about 90%. 
In order to determine the predictive values of the 
IGF-I concentration, patients were divided in age 
groups encompassing 10 years. For this reason, we 
arbritary chose to take 40 years as a cut-off point 
and calculated the matching IGF-I concentration, 
which was about 15 nmol/l. The sensitivity, speci­
ficity, accuracy and positive and negative predic­
tive values were calculated (11). 
Statistical analysis was performed using the un­
paired t-test (p-value depicted as p) or Spearman 
rank correlation test (p-value depicted as p*). 
RESULTS 
In healthy volunteers the IGF-I concentration de­
creased with age (Fig. 1, f^-0.829, p*<0.001). No in­
fluence of gender could be demonstrated. In pa­
tients with growth hormone deficiency, IGF-I con­
centrations appeared independent of age (p*-0.73). 
Again no statistical significant influence of gender 
could be demonstrated, nor could any relation be­
tween IGF-I concentration and etiology or type of 
surgery and/or radiation or duration of growth hor­
mone deficiency be demonstrated. 
Comparing the mean IGF-I concentrations of the pa­
tient and control groups in the various age cohorts, 
statistically significant differences for all but the el­
dest age cohort could be demonstrated (Table 1). 
Using the calculated cut-off concentration of 15 
nmol/l to define growth hormone deficiency re­
sulted in a sensitivity of 93% and a specificity of 
62% for the total population. The positive predic­
tive value was 73%, whereas the negative predic­
tive value was 89%. Analyses per decade (Table 2) 
showed that for the younger age cohorts up to 40 
years a high sensitivity (82 and 100%) was com­
bined with a high specificity (78% and 100%). Based 
on these data, we divided the patient population 
in two groups, one group consisting of patients 
younger than or equal to 40 years and the other 
one of patients older than 40 years. Below the age 
of 40 years the sensitivity was 90%, the specificity 
89%, the positive predictive value 93% and the 
negative predictive value 84% (Table 3). This means 
that IGF-I measurement can reliably be used as a 
method for screening these patients for growth hor­
mone deficiency. 
For patients above the age of 40 years sensitivity 
was 96%, the specificity and positive predictive val­
ue were low (48% and 59%, respectively). The ne­
gative predictive value was as high as 94% (Table 
3), indicating that IGF-I is a useful tool to exclude 
growth hormone deficiency in patients above the 
age of 40 years. 
Tab'e 2 - Predictive value ot'IGF-I using a cut-off concentration of 15 nmol/l forali decades. 
Age group (years) 
Sensitivity 
Specificity 
Accuracy 
Positive predictive value 
Negative predictive 
ι value 
20-30 
82.4% 
100% 
88 5% 
100% 
75.0% 
3 1 ^ 0 
100% 
77 8% 
91 3% 
87 5% 
100% 
41-50 
100% 
72 7% 
88 8% 
84.2% 
100% 
51-60 
87.5% 
41 2% 
56 0% 
4 1 2 % 
87.5% 
61 + 
100% 
28 6% 
50 0% 
37 5% 
100% 
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Table 3 - Predictive value of IGF-I using a cut-off concentration 
£40 years of age 
Sensitivity 90.3% 
Specificity 88 9% 
Accuracy 89 8% 
Positive predictive value 93 3% 
Negative predictive value 84.2% 
DISCUSSION 
In literature controversy exists about the use of IGF-I 
in the diagnosis of g r o w t h h o r m o n e deficiency. 
Most authors d id not correct for age and could not 
demonstrate a relation between serum IGF-I con­
centrations and the presence of GH deficiency in 
adul t patients ( 1 , 7-9). Only three groups, w h o 
made a correction for age, f o u n d a more useful re­
lat ion between serum IGF-I concentrat ions and 
growth hormone deficiency in adults (4-6). 
Our data extend the latter observations. Actually, 
w e were able t o demonstrate that at a cut-off con­
centration of 15 nmol/l of IGF-I, sensitivity, speci­
ficity and positive predict ive value are almost 9 0 % 
or even higher in patients with proven growth hor­
m o n e deficiency a g e d between 20 and 40 years. 
This means that the IGF-I concentration per se can 
be used as a rel iable t o o l f o r the diagnosis of 
growth hormone deficiency. Using our cut-off point 
of 15 nmol/l, f rom data published by de Boer et al. 
(5), we were able t o calculate that in their severe 
growth hormone deficient young (age between 20 
and 40 years) males, the sensitivity of IGF-I mea­
surement is 100%, the specificity 96%, the positive 
predictive value 8 2 % and the negative predictive 
value 100%. We extend this observation by demon­
strating for the first t i m e that in subjects over the 
age of 40 years plasma IGF-I values exceeding 15 
nmol/l virtually exclude growth hormone deficien­
cy (negative predictive value 95%). These data chal­
lenge the statement made by Ghigo et al. (4) that 
over the 40 years of age IGF-I measurements have 
no clinical value at all. With regards t o patients be­
low the age of 40 years, our findings are in line with 
the observations of Ghigo et al. who found, that, 
in patients between 20 and 40 years suffering from 
hypopituitarism with assumed growth homnone de­
ficiency plasma, IGF-I had 8.6% overlap with the 
normal population as opposed t o the age groups of 
41-60 and 61-80, in which the overlap was 50.0% 
and 92.3%, respectively. Recalculating the data 
from Juul et al. (6) showed that for the plasma IGF-
I measurement (cut-off2 SD scores) for patients with 
J S nmol/l 
>40 years of age 
sensitivity 96 3% 
specificity 48 6% 
accuracy 691% 
positive predictive value ' 59.1 % 
negative predictive value 94.4% 
a severe growth hormone deficiency (growth hor­
mone peak <5 pg/l) sensitivity was approximately 
80%, specificity was approximately 75%, and accu­
racy was about 78% (6). In summary, under the age 
of 40 years measuring plasma IGF-I provides a use­
ful t o o l t o diagnose g r o w t h hormone deficiency, 
whereas above the age of 40 plasma IGF-I values 
exceeding 15 nmol/l virtually exclude growth hor­
mone deficiency. 
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Gender Difference in Insulin-Like Growth Factor I 
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ABSTRACT 
GH production in healthy women is about thrice that in men Yet 
insulin-like growth factor I (IGF-I) levels are similar, suggesting 
a lower responsivity to GH in women In untreated GH-deficient 
adults, basal IGF-I levels are reportedly lower in females than in 
males, and the therapeutic recombinant human GH (rhGH) dose 
required to achieve optimal IGF-I levels is higher in the former, 
suggesting a pivotal role of estrogens on rhGH requirement in 
GH-deficient patients. We, therefore, analyzed our 2-yr data on the 
effect of rhGH on serum IGF-I in 77 GH-deficient patients (33 men, 
mean ± SD age, 37 2 ± 13.8 yr; 44 women, mean ± SD age, 36.9 * 
11.9 yr) with due attention to gender differences and to the effects 
of sex hormone replacement. Of the 44 women, 33 had estrogen 
substitution. Of the 33 men, 23 were on androgen replacement 
Patients (11 premenopausal women and 10 men) not on hormonal 
replacement were eugonadal. 
Baaal IGF-I levels in untreated GH-defident women were signif­
icantly lower than in men (8.8 ΐ 0.7 nmol/L vs 12.2 ± 0.9 nmol/L, Ρ < 
0 01), despite similar basal GH levels The daily rhGH dose per kg 
body weight required to normalize IGF-I in women was higher than 
m men, the difference being statistically significant at all time points 
(P < 0 05-0 01). The IGF-I increase (Δ) per IU GH/daykg over the 
24-month period was about twice higher in men than m women Also 
calculated on a weight basis, rhGH responsivity (rhGH responsivity = 
DURING CHILDHOOD, secretion of GH shows no dif­ference between boys and girls (1). However, at pu­
bertal age differences can be found between both sexes, in­
tegrated GH concentrations in young menstruating women 
being higher than in young men (2). At the adult age there 
is still a marked difference between both genders. Most stud­
ies show that GH secretion is higher in women than in men, 
both under basal conditions (3,4) and after stimulation (5,6) 
van den Berg et al. (4) reported that the mean daily GH 
production was thrice greater in women than in men, largely 
due to an amplitude-specific divergence in the pulsatile 
mode of GH secretion. This gender difference is closely re­
lated to estrogen secretion and possibly influenced by serum 
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(ÀlGFKnmol/U/dose (IU/day/kg)) was higher in men than in women 
at all time intervals (P < 0.05-0.01) 
Estrogen replacement m women significantly increased rhGH re-
quirement The rhGH dose per kg body weight required in estrogen-
substituted women was significantly higher than m nonestrogen-
substituted women (P < 0 01 at t = 18 and 24 months, respectively) 
In women on estrogen substitution, rhGH responsivity plateaued 
from 6 months on, whereas in eugonadal women without estrogen 
substitution the responsivity for rhGH increased over time In men, 
the reverse was true; rhGH responsivity increased over time in men 
on androgen substitution, but plateaued in men without androgen 
substitution 
The mechanisms underlying this gender difference are not known 
Differential influences of estrogens and androgens on the expression 
of the GH receptor gene and IGF-I messenger RNA may be operative 
The present study confirms short-term data published in the lit-
erature on a sex difference in rhGH dose requirement in GH-deficient 
patients. It furthers extends the data by demonstrating that this sex 
difference in GH responsivity persists and changes during the 24 
months of the study Moreover, it shows that estrogen replacement 
blunts the IGF-I response to rhGH m women, whereas in men with 
androgen substitution the responsivity increases over time, thus 
bearing a nek of undertreatment in women and overtreatment in 
men. (J Clm Endocrinol Metab 86: 1121-1125, 2000) 
testosterone, as well (7). Indirect evidence for estrogen in-
fluence on GH secretion also can be derived from the fact that 
during the late follicular phase of the menstrual cycle integrated 
GH concentrations are higher than during the early folbcular 
phase and luteal phase (8). Furthermore, oral estrogen admin-
istration has been shown to increase integrated GH concentra-
tion both in healthy pre- and postmenopausal women by virtue 
of a lesser negabve feedback due to lowered serum insuhn-like 
growth factor I (IGF-I) concentration (9). 
Despite higher GH levels in healthy adult women com-
pared with healthy adult men, no gender difference in basal 
serum IGF-I concentrations has been demonstrated (10,11) 
Remarkably, however, where estrogen administration low-
ers IGF-I concentrations in healthy women, in men a direct 
positive correlation between serum testosterone and IGF-I 
levels has been reported (12), compatible with a gender dif-
ference in IGF-I control caused by sex steroids. 
In contrast to healthy men and women, IGF-I levels in 
GH-deficient adults are lower in women than in men (13-15). 
40 
Furthermore, Burman et al. (13) a n d Drake et al. (15), in rather 
shor t s tudies (9 and 3 m o n t h s , respectively), observed a gen­
der difference in recombinant h u m a n G H (rhGH) require­
ment , w o m e n needing h igher r h G H doses and longer t ime 
than m e n to achieve the s a m e clinical effects a n d IGF-I levels. 
Unexpectedly, however, in the GH-deficient w o m e n n o sta­
tistically significant effect of estrogen substitution on IGF-I to 
r h G H responsiveness w a s found (13, 15). This may be d u e 
part ly to the small n u m b e r of w o m e n studied, the rather 
short t reatment period, or to the substitution method used 
(13, 15). In the rhGH-deficient m e n the effect of androgen 
subst i tut ion on r h G H r e q u i r e m e n t w a s not evaluated at all. 
This knowledge p r o m p t e d us to: 1) analyze our data on 
s e r u m IGF-I-titrated r h G H treatment in a large cohort of 77 
GH-deficient adults not only to confirm the presence of a 
g e n d e r difference in r h G H requirement after short-lasting 
G H replacement, but also to assess its persistence after m o r e 
pro longed r h G H treatment; a n d 2) extend literature data on 
this gender difference by evaluat ing the effect of sex hor­
m o n e substitution on IGF-I responsiveness to r h G H in 
w o m e n a n d also in men. 
Subjects a n d M e t h o d s 
Patients 
Seventy-seven patients (33 men, age 37 2 i 13.8 yr (mean ± so); 44 
women, age 36.9 ± 11.9 yr) suffering from GH deficiency, were included 
in this analysis GH dehaency was diagnosed when an arginine test 
revealed a peak GH concentration below 10 mU/L (16). Thirty-three 
women and 23 men received sex hormonal substitution therapy Three 
of the women, all over 50 yr of age, received transdermal estrogen 
replacement, and the remaining 30 had oral estrogen substitution. Most 
men received parental androgen substitution (n = 19), whereas only four 
had oral replacement therapy. None of the men had transdermal sub­
stitution. Twenty-one patients (11 premenopausal women and 10 men) 
were eugonadal. 
Due to pituitary pathology, most pahents had multiple pituitary 
deficiencies and addihonally received adequate hormonal replacement 
therapy. Pituitary pathology was idiopathic (mulhple or isolated) m 19 
patients and was caused by pituitary adenoma m 23 pabents; cramo-
pharyngioma in 13 pabents; congenital lesions m 7 patients, cerebral 
tumors (meningioma, epipharmx carcmoma, germmoma, rhabdomyo­
sarcoma, and meduUoblastoma) in 7 patients, Sheehan's disease m 2 
pabents, trauma m 2 pabents; and empty sella, meningitis, histocytosis 
X, and agenesis of the septum pellucidum each m 1 patient Most pa­
tients had been treated surgically with or without subsequent radiahon 
therapy. Duration of GH dehaency varied from 1-36 yr. AU pahents 
signed an informed consent to the protocol, which was approved by the 
University Hospital Ethical Committee. 
Pahents were treated with rhGH (Genotropm, Pharmacia-Upphn; or 
Humatrope, Eh Lilly & Co ) m varying doses. The treatment goal was 
to achieve an IGF-I concentration falling within the age-corrected normal 
range (mean ± 2 so) for our laboratory (11) To reach this goal, the rhGH 
dose was adjusted at every visit. The time interval between the visits was 
6 months Treatment durabon was 24 months. Serum IGF-I values were 
measured every 6 months. GH was measured by direct RIA using the 
WHO standard for human GH 80/505. The interassay coefficient of 
variation (CV) was 9 2,7 8,5 0%, and 6.0% at GH concentrahons of 4 7, 
10.6,20.8, and 53.5 mE/L (11). IGF-I was determined by an m-house RIA. 
The mtia-assay CV, expressed as the relabve duphcate CV at concen­
trahons between 5 and 50 nmol/L, was 5.7%. The interassay CV was 
9 4% at a level of 8.4 nmol/L, 4.1% at 29.8 nmol/L, and 6 5% at an IGF-I 
concentration of 41.7 nmol/L (17) 
Responsivity to rhGH was defined as the quohent of the rhGH-
induced AIGF-I (nmol/L) and the dose (IU/daykg) used m the same 
penod Or m formula: rhGH responsivity = (MGFl (nmol/L)/dose 
(IU/day/kg)) (AIGF-I = change of IGF-I from basehne; dose = dose 
used during the last 6 months). 
Statistics 
Values menhoned are means ± SEM, except for the age were mean ± 
so is used. The unpaired Student's t test was used to evaluate differences 
found between two groups 
R e s u l t s 
Serum GH and IGF-I levels before rhGH therapy 
N o difference in baseline- or arginme-stimulated s e r u m 
G H levels could be demonst ra ted between GH-deficient m e n 
and w o m e n In both m e n a n d w o m e n , basal G H levels were 
less than 2 m U / L . After arginine provocat ion a slight in­
crease in G H concentration w a s seen in a minority of the 
patients ( m a x i m u m s e r u m G H concentration, 4 m U / L ) 
Baseline s e r u m IGF-I levels, however, w e r e significantly 
lower in w o m e n than in m e n (8 8 ± 0.1 vs 12.2 ± 1 0 n m o l / L , 
Ρ < 0.01). Women on estrogen substitution had similar IGF-I 
levels as those w i t h o u t sex steroid substitution. The same 
w a s t rue for m e n wi th or w i t h o u t a n d r o g e n therapy 
Effects of gender on rhGH dose, serum IGF-I concentration, 
and rhGH responsivity 
rhGH dose. The r h G H dose per kg b o d y weight ( I U / d a y k g ) 
required m all w o m e n w a s significantly higher than that for 
m e n at all t ime intervals (P < 0.05-0.01). In men, both on and 
wi thout androgen subshtut ion, the dose required decreased 
over time, the difference between 6 m o n t h s and 24 m o n t h s 
being statistically significant (P < 0 05), w h e r e a s it p lateaued 
in w o m e n (Fig. 1). 
After the titration phase, the daily r h G H dose required to 
normalize IGF-I levels in w o m e n , both on and w i t h o u t re­
placement therapy, remained virtually u n c h a n g e d . In men, 
the dose required decreased over time, from 1.73 ± 0.16 
I U / d a y at t = 6 m o n t h s to 1.31 ± 0 23 I U / d a y at t = 24 
m o n t h s (P < 0 05) (Fig. 1). Al though the daily r h G H dose 
required to normal ize IGF-I in w o m e n w a s higher than in 
m e n over the whole t reatment period, the difference reached 
statistical significance only after 24 m o n t h s of therapy (2.05 ± 
0 23 I U / d a y for w o m e n against 1.31 ± 0 23 I U / d a y for men; 
Ρ < 0.05). 
Serum IGF-I levels and rhGH responsivity As m e n t i o n e d 
earlier, base l ine s e r u m IGF-I levels w e r e significantly 
lower in w o m e n t h a n in m e n (P < 0 01). After s tar t ing 
r h G H t r e a t m e n t , IGF-I levels increased in b o t h m e n a n d 
w o m e n (from base l ine to 6 m o n t h s , Ρ < 0.01). After this 
initial increase, h o w e v e r , n o further rise o c c u r r e d e i ther in 
m e n or in w o m e n . 
The increase in r h G H responsivity (i.e. the increase of IGF-I 
per dose r h G H corrected for weight) over time was m o r e 
pronounced in m e n than m w o m e n , the difference being 
statìsbcally significant (P < 0.05 at t = 6 and t = 24 months 
and Ρ < 0.01 at 12 a n d 18 months) (Fig. 2) a t all t ime intervals 
This w a s d u e part ly to the fact that r h G H responsivity vir­
tually remained u n c h a n g e d over t ime in w o m e n (P > 0.10), 
b u t a lmost doubled in m e n (difference between t = 6 a n d 18 
months ; Ρ < 0.01) (Fig. 2). 
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Effects of sex hormonal substitution on rhGH dose, serum 
IGF-I concentration, and rhGH responsivity 
Estrogen replacement in tvomen: rhGH dose. As mentioned ear-
lier, 33 of 44 women received estrogen substitution (30 oral 
and 3 transdermal estrogen substitution) and 11 eugonadal 
women did not. Baseline IGF-I levels were virtually similar 
in both groups (9.4 ± 0.9 vs. 7.0 ±1.6 nmol/L, Ρ > 0.10). The 
weight-corrected rhGH dose required to achieve adequate 
IGF-I levels was at all tune intervals higher in the estrogen-
treated women than in the women without estrogen substi­
tution, but the difference was only statistically significant at 
18 months (0.038 ± 0.003 vs. 0.028 ± 0.005 IU/daykg) and 
24 months [0.033 ± 0.001 vs. 0.024 ± 0.001 IU/daykg (P < 
0.05)]. 
After 6 months of treatment, the mean daily dose for 
women using estrogens was 2.17 ± 0.18 IU/day and for 
women without estrogens was 1.59 ± 0.26 IU/day, being 
statistically significant (P < 0.01). During the whole treat­
ment period of 24 months this difference remained statisti­
cally significant (P < 0.05). At 24 months, the daily rhGH 
doses were 2.50 ± 0.25 IU/day and 1 50 ± 0.18 IU/day, 
respectively. 
Exclusion of the data from the three women on transder­
mal estrogen replacement did not change the outcome of the 
analysis (data not shown). 
Serum IGF-I levels and rhGH responsivity. In response to rhGH, 
serum IGF-I initially increased equally in both groups of 
estrogen-substituted and nonsubstituted women. From 6 
months onward, however, IGF-I levels plateaued in the es­
trogen-substituted women, but increased in the women 
without estrogen, although this difference never reached 
statistical significance (P > 0.10). At all time intervals from 
12 months on there was a tendency (P < 0.10) to lower IGF-I 
increments in the estrogen-treated group. 
The difference in rhGH responsivity between substituted 
and nonsubstituted women was statistically significant (P < 
0.01 both at 18 and 24 months). In women without estrogen 
substitution, responsivity to rhGH almost doubled over time 
(P < 0.05 for the change from t = 6 months to t = 24 months). 
In the women on estrogen substitution the rhGH responsiv­
ity plataued from 6 months on (Fig. 3). 
Again the exclusion of the data from the three women on 
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transdermal estrogen replacement did not change the out­
come of the analysis (data not shown). 
Androgen replacement in men: rhGH-dose. After 6,12,18, and 
24 months of treatment, the daily rhGH dose per kg body 
weight required to achieve adequate IGF-I levels was not 
statistically significant different between men with and with­
out testosterone replacement. The same holds for the daily 
doses of rhGH in both groups of men (data not shown). 
Baseline serum IGF-I levels in both groups were similar 
(12.0 ± 1.0 nmol/L in the androgen-substituted men vs. 
12.9 ± 2.3 nmol/L in the eugonadal men (P > 0.10). 
rhGH responsivity, however, doubled over time in the 
androgen-substituted group of men (increase from 6-24 
months, Ρ < 0.01), not in the men without androgen sub­
stitution, reflecting an increase of rhGH responsivity by ex­
ogenous androgen therapy during continued rhGH admin­
istration (Fig. 3). 
Diecussion 
The present study revealed an overt sex difference in rhGH 
requirement in GH-deficient adults, persisting for 24 months. 
To achieve similar IGF-I increments, higher rhGH doses were 
needed m women than in men. This gender difference was 
even more pronounced as GH-deficient men achieved higher 
IGF-I increments than women at lower daily rhGH doses 
corrected for weight. Using standardized rhGH doses for 
GH-deficient women and men, Burman, et al. (13) found a 
similar sex difference m IGF-I responsivity to rhGH in GH-
deficient adults, treated for 9 months. This gender difference 
in IGF-I responsivity was accompanied by a more pro­
nounced loss of body fat, fall in total and low-density li­
poprotein cholesterol, and in bone turn over m men than in 
women on rhGH therapy (13). Very recently Drake et al. (15) 
also reported a gender difference in IGF-I responsivity to 
rhGH m GH-deficient adults treated for 3 months, the daily 
dose being 50% higher in females than in males. The time to 
achieve the maintenance dose was also significantly longer 
in women. The data in the present study indicate that the 
gender difference m rhGH requirement persists even after 24 
months of rhGH treatment. 
Obviously differences in estrogen concentrations have 
been incriminated as a possible underlying cause for the 
gender difference in rhGH requirement. Estrogens report­
edly have distinct effects on the somatotropic axis (compare 
Introduction). A reduction in IGF-I levels during oral estrogen 
replacement has been observed in healthy postmenopausal 
women (18), whereas Holloway et al (19) found a blunted 
effect of rhGH on metabolic indices and body composition 
changes in healthy postmenopausal women receiving estro­
gens as compared with women without estrogen substitu­
tion. These data are m Ime with the idea that due to a first 
pass effect of estrogens the IGF-I synthesis in the liver is 
diminished. Indeed, after estrogen administration, a de­
crease in the expression of GH receptor gene and IGF-I mes­
senger RNA has been found in laboratory animal hepato-
cytes (20,21). Therefore, it was remarkable that in contrast to 
healthy women Burman et al (13), in a rather small group of 
adult GH-deficient women with (n = 8) and without (n = 7) 
estrogen replacement, did not find a difference in rhGH-
induced IGF-I concentration between both groups. After 3 
months of treatment, Drake et al (15) also failed to demon­
strate such a difference both in median rhGH doses and IGF-I 
increment in response to rhGH in GH-deficient women sub­
divided by gonadal status and use of estrogen replacement 
In contrast, in the present study in a larger group of GH-
deficient adults treated for a longer period of 24 months, an 
overall difference in IGF-I responsivity to rhGH was found 
between women with and without estrogen replacement. 
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Estrogen significantly blunted the IGF-I response to rhGH, 
IGF-I levels plateaing from 6 months on after the initial 
increase. The discrepancy of our results with those of both 
other studies may reside in the longer treatment period and 
the larger number of GH-deficient women m our study. 
In our cohort of adult GH-deficient males, the group not 
receiving androgen replacement had lower rhGH respon-
sivity than men on androgen replacement over the whole 
time period. At 18 months and 24 months the difference was 
statistically significant. Unlike estrogen replacement in 
women, which blunted the IGF-I response to rhGH, in the 
androgen-treated males a steady increase in IGF-I respon-
sivity was observed over the 24-month treatment period, 
compatible with an androgen-induced rise in rhGH respon-
sivity over time induced by exogenous androgens. This find-
ing is in line with observations of other authors reporting 
increases in circulating IGF-I levels in response to androgens 
in eugonadal men (12), hypogonadal men (22), and in boys 
with delayed puberty (23,24). The changes in rhGH respon-
sivity over time in men and women as mentioned above 
indicate that there is a risk of overtreatment of men, espe-
cially men on sex hormone replacement, and undertreatment 
of women, especially women on estrogen substitution. The 
mechanism by which androgens increase IGF-I responsivity 
to rhGH are not known. In castrated rabbits the expression 
of the GH receptor gene in the liver not only has been re-
ported to decrease after estrogens, but rather to increase after 
testosterone. 
Summarizing, a gender difference in rhGH dose require-
ment and IGF-I responsivity to rhGH m GH-deficient adults 
was observed in line with recent literature. The present study 
further extends these data, demonstrating that this gender 
difference persists after longer times of rhGH therapy (24 
months) and that estrogen replacement in GH-deficient 
women blunts the IGF-I response to rhGH, whereas in men 
androgens increase the responsivity to rhGH over time. This 
may be associated with a risk of overtreatment of men, es-
pecially those on androgen substitution, and undertreatment 
of women, especially those on estrogen substitution. 
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Gender Differences in rhGH-Induced Changes in Body 
Composition in GH-Deficient Adults 
J A N P . T. S P A N , GERLACH F . F . M. P I E T E R S , F R E D G. J . S W E E P , A D R. M. M. H E R M U S , AND 
A N T H O N Y G. H . S M A L S 
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of Chemical Endocrinology (F.G.J.S.), University Medical Centre Nijmegen, Geert Grooteplein 8, The Netherlands 
In GH-deficient adulte, rhGH baa pronounced effects on total 
body water, fat free mass, and fat mass. Recently, we observed 
a gender différence in IGF-I responsi vi ty to rhGH that was sex 
steroid dependent. The aim of the present study was to assess 
the effect of rhGH therapy on body composition parameters 
with due attention to the gender differences in biological re-
sponeiveness to rhGH. Forty-four women [38.9 ± 11.9 yr 
(mean ± SD)] and 33 men (37.2 ± 13.Θ yr) with GH deficiency 
were studied every β months during 2 yr. The treatment goal 
was to achieve IGF-I levels within the age-adjusted normal 
range. Total body water, fat free mass, and fat mass were 
measured by biolmpedantiometry. To reach the treatment 
goal, the dally rhGH dose (IU/kg/d) had to be significantly 
higher in women than in men at all time intervals. During 
rhGH therapy, total body water and fat free mass increased 
significantly in both men and women (P s 0.01 by ANOVA), but 
changes were more pronounced in men. Fat mass decreased 
during rhGH treatment and reached its nadir at β months, 
which was more pronounced in men than in women (P = 0.02 
by ANOVA). After the initial decrease, fat mass increased 
again and reached baseline values after 2 yr of treatment. In 
SO O N AFTER THE introduction in 1957 of G H therapy in children, it appeared that G H administrat ion not only 
influenced skeletal g rowth b u t also had significant effects on 
b o d y composit ion (1, 2). In GH-deficient adults, the first 
short-term controlled studies of the effect of G H also re­
ported p r o n o u n c e d effects on muscle a n d fat mass (3, 4) as 
well as on b o d y fluid (5). Recently, we (6,7) and others (8-10) 
observed a gender difference in r h G H dose requirement and 
IGF-I responsivity to r h G H in GH-deficient adul t s treated for 
24 months . M e n appeared m o r e sensitive to r h G H than 
w o m e n . Furthermore, we demonstrated that oral estrogens 
significantly increased r h G H requirement in women, 
whereas androgens decreased r h G H requirement in men. 
Very recently. Cook et al. (11) and Janssen and colleagues (12) 
confirmed the estrogen effect. 
Until now, only a few rather short-term studies (9-12 
months) have been publ ished dealing with a gender differ­
ence m rhGH-induced changes m body composition. Johan­
sson et al (9) found a greater loss of total body fat in adul t 
GH-deficient m e n treated for 9 m o n t h s with r h G H than in 
w o m e n . C u n e o et al (10) reported greater fat free mass (FFM) 
increments in GH-deficient m e n treated with r h G H for 12 
m o n t h s than m w o m e n . Very recently, Hayes et al. (13) re-
Abbreviahons FFM, Fat free mass, FM, fat mass; TBW, total body 
water. 
both men and women, the total body water and fat free mass 
increases were closely related to the IGF-I increments (P < 
0.001 by Pearson's correlation test). The decrease in fat mass 
correlated significantly with the increase in IGF-I in men (r = 
—0.Θ9, Ρ < 0.001), not in women. Confirming our earlier data, 
IGF-I responslvity to rhGH was significantly higher in men 
than in women at all time intervals (P < 0.01 by ANOVA). Total 
body water and fat free mass responsivities were also higher 
in men than in women (P < 0.01 by ANOVA). In conclusion, 
gender differences in IGF-I responsivities to rhGH are accom­
panied by gender différences in the extent of body composi-
tion changes to rhGH. Probably because of these gender dif-
ferences in IGF-I responslvity, the increases of total body 
water and fat free mass to rhGH replacement were greater in 
men than in women. Remarkably, however, in men, only total 
body water and fat free mass responses relative to changes in 
IGF-I increased during the 2 yr of rhGH therapy (P = 0.02 and 
0.01, respectively, by ANOVA). In our opinion, this phenome-
non might be explained by the increasing target organ sen-
sitivity to IGF-I over time. (J Clin Endocrinol Metab 86: 
4161-4106, 2001) 
ported a beneficial effect of rhGH treatment in 12 GH-defi-
cient adul ts for 12 months only in men, not only wi th respect 
to the increase in total body water (TBW) and lean body mass 
but also wi th respect to the decrease in fat mass (FM) In a 
very large s tudy dealing with 665 GH-deficient adul ts 
treated for 1 yr with rhGH, Bengtsson et al (14) reported a 
greater decrease in w a i s t / h i p ratio, but not in FM, in men 
than m w o m e n 
These data p rompted us to s tudy the effects of rhGH 
therapy for a longer period (2 yr) on body composition pa-
rameters with due a t tenhon to gender and IGF-I responslvity 
to rhGH. 
Subjects and Methods 
Paiienis 
Seventy-seven patients [44 women, age 36 9 ± Π 9 yr, 33 men, age 
37 2 ± 13.8 yr (mean ± so)] with GH deficiency were included m this 
analysis Pabents were on GH substitution for at least lyr GH deficiency 
was diagnosed when an arguirne test revealed a peak GH concentra­
tion < 10 mU/hter (13) Only pabents with hypothalamic-pituitary 
pathology or patients treated with GH in childhood were exposed to an 
arginine test. Thirty-three women and 23 men received sex hormone 
substituhon therapy (Table 1) Three of these women, all older than 50 
yr, received transdermal estrogen replacement, the remaining 30 women 
had oral estrogen subshtution Nineteen men received parenteral an­
drogen substitution, whereas only 4 had oral replacement therapy None 
of the men had transdermal subshtution Twenty-one patients (11 pre­
menopausal women and 10 men) were eugonadal. Fifty-seven patients 
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TABLE 1. Patients with idiopathic GH deficiency and multiple 
hormonal deficiencies 
Women Men 
Idiopathic GH deficiency 7 12 
Multiple hormonal deficiencies 38 31 
Hypothyroidiem 3Θ 31 
Hypocortisolism 34 23 
Hypogonadahsm 33 23 
Diabetes insipidus 15 10 
received corticosteroid replacement therapy (Table 1). Sixty-nine pa­
tients needed thyroid hormone substitution (Table 1). Hormone replace­
ment was considered adequate when the patients were euthyroidal 
(serum TA between 54 and 154 nmol/liter), euadrenal (morning plasma 
Cortisol between 0.19 and 0 55 μτηοΙ/ΙιΙθΓ), and eugonadal (men, tes­
tosterone between 11 and 45 nmol/liter, women, midcycle estradiol of 
350-1800 pmol/liter) 
Pituitary pathology was idiopathic m 19 pabents In the remaining 58 
patients, rhGH deficiency was caused by pituitary adenoma m 23 pa­
tients, craniopharyngioma m 13 patients, congenital lesions in β pabents, 
other intracranial tumors m 7 patients (meningioma, epipharynx carci­
noma, geimmoma, rhabdomyosarcoma, medulloblastoma), Sheehan's 
disease m 2 pabents, trauma m 2 pabents, and empty sella, memngihs, 
and histocytosis X each m one patient. Most patients (n = 47) had been 
treated surgically. Eleven patients received radiotherapy 2-26 yr before 
the start of rhGH substitution. The duration of GH dehaency vaned 
from 1-36 yr. All pabents signed an informed consent to the protocol, 
which was approved by the University Hospital Ethical Committee. 
Patients were treated with rhGH (Genotropin, Pharmacia & Upjohn, 
Ine, Stockholm, Sweden; or Humatrope, Eli Lilly & Co, Indianapolis, 
IN) m varying doses The treatment goal was to achieve an IGF-I con­
centration within the age-corrected—not gender-corrected—normal 
range (mean ± 2 so) for our laboratory (15). All pabents started with 1 
lU/d, and rhGH dose was adjusted each visit if necessary. The visits 
were monthly during the first 6 months and twice a year thereafter. Data 
for up to 24 months were included in this analysis. Serum IGF-I con­
centration and TBW, FM, and FFM were measured every 6 months Not 
all pabents had a complete data set, because we included all patients 
with at least 1 yr of GH subshtuhon. For the withm-subject time X 
gender effect, a subset of 44 pabents (24 women, age 36 3 ± 12.7 yr, 20 
men, age 37 5 ± 131 yr) was used. This subgroup of pabents had a 
complete data set. Serum IGF-1 was determmed by RIA as described 
previously (15). Body composibon parameters were measured using 
bioimpedance analysis with the Akem 101 device (Equip Medikey, 
Gouda, The Netherlands). Apparatus-speohc conversions as deter­
mmed by the manufacturer were used 
TBW responsivity was dehned as ATBW (liters)/rhGH dose (IU/ 
kg/d); FM responsivity was defined as ΔΡΜ (kg)/rhGH dose (IU/kg/ 
d); and FFM responsivity was defined as AFFM (kg)/rhGH dose 
(IU/kg/d) 
Statistical methods 
Data are given as means ± SEM, except for age, for which means ± 
so are used. Stabsbcal significance of the differences between genders 
at baseline was calculated using Student's I test (significance denoted by 
P). Treatment effects over bme and between genders during treatment 
were assessed using ANOVA (significance denoted by P*). Conelahons 
between responsmbes of IGF-I, FM, FFM, and TBW to rhGH were 
calculated using Pearson's correlation test (significance denoted by P") 
Statistics were calculated using SPSS 9.0 for Windows (SPSS, Ine, Chi­
cago, IL) 
To exclude major bias, the results of the 77 pabents, including some 
with an incomplete data set, were compared with a subset of pabents 
(n = 44) with a complete data set. 
R é s u l t e 
Baseline body proportions, rhGH dose, and IGF-I values 
Baseline weight did not differ significantly between the 
gender s at the start of G H therapy (women, 72.9 ± 2.9 vs. 
men, 77.1 ± 3.1 kg; Ρ > 0.10). The m e a n TBW (31.8 i 0 8 vs 
41.2 ± 1.3 Uters) a n d FFM (44.6 ± 1.5 vs. 56.9 ± 2 1 kg) were 
both significantly lower in w o m e n t h a n in m e n (P < 0.001); 
the hip to waist ratio (1.13 ± 0 01 vs. 1.06 ± 0.01) a n d the FM 
(25.8 ± 1.5 cs. 21.6 ± 1 . 6 kg) were higher (P < 0 01) in w o m e n 
Baseline s e r u m IGF-I (8.8 ± 0.1 vs. 12.2 ± 1 . 0 nmol/l i ter) w a s 
significantly lower in GH-deficient w o m e n than in men (P < 
0.05). Baseline IGF-I SDS w a s - 1 . 9 ± 0.9 for w o m e n a n d 
- 1 . 4 ± 0.8 for men. 
Influence of gender on rhGH dose and IGF-I responsiveness 
Confirming earlier data, m e n n e e d e d significantly lower 
r h G H doses (with a n d wi thout correction for weight) than 
w o m e n . Yet, higher s e r u m IGF-I levels were achieved in men, 
which is in line wi th their higher r h G H responsivity (data not 
shown). 
Effects of gender on rhGH-mduced changes in 
body composition 
N o statistically significant changes in weight (Fig. 1) or hip 
to waist ratio (data not shown) were observed dur ing r h G H 
therapy in w o m e n or m e n (P* > 0.10). 
r h G H replacement induced an increase in TBW (P* < 0.01) 
in both m e n a n d w o m e n . From 6 m o n t h s on, TBW increased 
FIG 1 rhGH-mduced changes in body composition parameters in 
both men and women. 
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further only in men (P* = 0 02) The TBW increase was more 
pronounced m men than m women (P* = 0 01) (Fig 1) 
FM decreased significantly (P* < 0 01 for the first 6 
months) m both men and women, but the maximum decrease 
m FM during rhGH substitution was more pronounced m 
men (4 6 ± 0 9 rs 1 4 ± 0 5 kg, respectively, P* = 0 02) (Fig 
1) At 24 months, FM values had returned to baseline m both 
men and women 
During the first 6 months of treatment, FFM increased 
significantly during rhGH therapy m both men and women 
(P* s 0 01) From 6 months on, a tendency to further increase 
was observed only m men The sex difference was statisti­
cally significant (P* = 0 05) (Fig 1) 
Responsivity of body composition parameters related to the 
weight-corrected rhGH dose 
TBW responsivity [i e ATBW (Uters)/rhGH dose (IU/kg/ 
d)] showed a statistically significant mcrease over time only 
m men (P* < 0 01) (Fig 2) TBW responsivity was more 
pronounced m men than in women (P* < 0 01) 
Although FM responsivity initially decreased significantly 
only m men, it remained virtually unchanged during the 
whole observation period in both men and women (P* > 
0 10) FM responsivity was significantly more pronounced m 
men than m women (P* < 0 01) (Fig 2) 
FFM responsivity increased significantly during rhGH 
therapy (P* s 0 01) only m men, agam not in women (P* > 
010) (Fig 2) FFM responsivity was more pronounced in men 
than in women (P* < 0 01) 
Changes of body composition during rhGH therapy relative 
to changes in IGF-I 
At all hme points, there was a statistically significant cor­
relation between baselme IGF-I levels and the changes in 
TBW (r = +0 37, P** < 0 05) and FM (r = - 0 38, P** < 0 05) 
but not m FFM (r = +0 26, P** > 010) m the group as a whole 
For women, there was a significant correlation between base­
lme IGF-I levels and AFM (r = - 0 52, P " < 0 01) but not 
ATBW (r = +028, P " > 0 10) or AFFM (r = +0 11, P " > 
0 10) For men, no statistically significant correlation between 
baselme IGF-I and ATBW, AFM, or AFFM could be 
demonstrated 
There was a statistically significant mcrease of TBW re­
sponsivity relative to AIGF-I [ie ATBW (liters)MIGF-I 
(nmol/hter)] only m men (P* < 0 02) (Fig 3) In both men and 
women, the mcrease m TBW during rhGH therapy was di­
rectly correlated to the increases in IGF-I, although the cor­
relation coefficient was lower m women than m men (wom­
en, r = +0 81, Ρ** < 0 005, men, r = +0 95, P " < 0 005) 
FM responsivity related to AIGF-I remained virtually 
FIG 2 Responsivity of TBW, FM, and FFM in men and women dur­
ing 2 yr of treatment 
FIG 3 Changes m TBW, FM, and FFM relative to the changes in 
IGF-I 
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unchanged during the 24 months of rhGH therapy in both 
genders. Remarkably, the decrease in FM seen during 
the first 6 months of rhGH substitution was statistically 
significantly correlated with the IGF-I increase only in 
men (r = -0.89, P " < 0.001), not in women (r = -0.65, 
P " > 0.10). 
FFM responsivity related to AIGF-I increased significantly 
during rhGH therapy (P* < 0.01) in men, but again not in 
women. There were no statistically significant differences 
between the relative FFM responsivities in men and women 
at any time. The changes in FFM correlated directly with the 
IGF-I increases in both men and women, although again the 
correlation coefficient was lower in women (r = +0.80, P** 
< 0.001) than in men (r = +0.95, P " < 0.001). 
Bias estimation 
The incompleteness of the data sets of some patients could 
have introduced a confounding factor that could give rise to 
some bias. To get an idea of the extent of the bias introduced 
by the different subjects participating in different compari-
sons at different times, a subgroup of 44 pa bents with a 
complete data set was analyzed. The baseline characteristics 
of the subgroup were not different from those of the complete 
group. Therefore, the subgroup of 44 patients can be con-
sidered a random sample of the complete group of 77 pa-
tients. Calculations of the time effect m this subgroup re-
sulted in comparable statistical significance with the 
exception of TBW in men during the last 18 months of treat-
ment, for which P* changed from 0.02 in the complete group 
to <0.01 in the subgroup. The gender effect was the same in 
both populations. With respect to the ratios used, all statis-
tical significances were the same in both populations. This 
indicates that the bias introduced by the incompleteness of 
the data set is marginal compared with the effects and does 
not interfere with the conclusions drawn from the complete 
population. 
Discuesion 
This study demonstrated that TBW and FFM increased 
significantly during 2 yr of rhGH therapy, confirming short-
term data from others (8,9,11,13,14). The hip to waist ratio, 
however, did not change during the rhGH replacement, 
which is at vanance with the results of Bengtsson et al. (14), 
but confirms the data of others (8, 9). Remarkably the in-
creases in TBW and FFM were more pronounced in men than 
in women, reflecting the higher IGF-I responsivity in men, 
which was confirmed in this study. The FM decrease was also 
more pronounced in men than in women at 6 months. After 
this period, the changes in FM leveled off and were no longer 
statistically significantly different between the genders. 
These data are partially in line with the findings reported in 
short-term studies after administration of fixed doses of GH 
(10,13,14). The dose used in those studies was conventional 
(i.e. 0.25 lU/kg-wk), which gives rise to supraphysiologic 
IGF-I concentrations, especially in men (10). In the present 
study, comparable results were obtained using lower doses 
of GH (0.167 ± 0.015 IU/kg-wk), indicating that rhGH titra-
tion using IGF-I levels is as effective as a higher fixed dose 
when body composition parameters are taken into account. 
During treatment, TBW and FFM responsivities increased m 
men but not m women. FM responsivity remained stable 
during the rhGH replacement m both men and women. Our 
data partially confirm the findings of Johansson et al (9), who 
found a gender difference in loss of body fat after 9 months 
of treatment with a fixed rhGH dose (0 25 IU/kg-wk) Cuneo 
et al. (10), m a 1-yr mulbcenter study, reported a sex differ-
ence m FFM in favor of men after 6 and 12 months of sub-
stitution with rhGH (fixed dose of 0.25 IU/kg/d), however, 
no gender difference was observed in FM decrease. Our data 
confirmed the finding of Hayes et al. (13), who, in a short-
term study of 9 months, observed a statistically significant 
increase in TBW and FFM only in men and a decrease m FM, 
again only in men In our study, which lasted 2 yr, we 
demonstrated that using IGF-I-titrated rhGH substitution, 
the relative responsivity of FM was not influenced by gender 
if there was an equal IGF-I concentration 
The absolute TBW and FFM changes m response to rhGH 
were directly correlated to the increase in IGF-I, the corre-
lation coefficients, however, were higher in men than in 
women. Unlike in men, AFM and AIGF-I were not statisti-
cally significantly correlated in women. These latter data are 
in line with the data of Johansson et al. (9), who also observed 
a significant negative relation between the decrease in total 
body fat and the increase in serum IGF-I only in men. Other 
authors did not mention such a relationship (13, 14) 
One may assume that the more pronounced changes m 
body composition parameters in men can be explained by the 
greater changes in IGF-I found. This, however, appears not 
to be the only reason, because in our study the TBW and FFM 
increments in men relative to the AIGF-I actually increased 
during the 2 yr of rhGH treatment. In our opinion, this 
phenomenon might be explained by increasing target organ 
sensitivity to IGF-I over time. For FM, no such time-related 
change was found for men or for women. 
Previously, we demonstrated increasing responsivity of 
IGF-I to rhGH in androgen-treated men (7, 8) with the risk 
of overtreatment. Unfortunately, m the present study, it was 
not possible to unravel the modulating role, if any, of an-
drogen replacement on the relative responsivity of body 
composition parameters, because almost all men already re-
ceived androgen substitution before the start of rhGH re-
placement. Similarly, oral estrogen replacement may have 
attenuated the beneficial effect of rhGH-induced changes in 
body composition in GH-deficient women. Because the ma-
jority of the women had oral estrogen substitution, this may 
have led to relative resistance to rhGH (12) Further studies 
are necessary to assess the role of oral estrogens on the 
relative responsiveness to rhGH-induced IGF-I increase 
In summary, the present study demonstrates that the 
greater IGF-I responsivity to rhGH in GH-deficient men than 
in women is accompanied by more pronounced changes m 
TBW and FFM in the former. FM initially decreased, but after 
24 months of treatment, baseline values were reached, indi-
cating only a temporary effect of rhGH on FM in both men 
and women. Remarkably, in men only, TBW and FFM re-
sponses relative to IGF-I increased during the 2-yr treatment 
period, which in our opinion suggests increasing target or-
gan sensitivity to IGF-I over time. The permissive role, if any. 
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of androgens in facilitating this response remains to be 
elucidated. 
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Abstract 
Short-term substitution studies (up to 6 months) in GH deficient adults demonstrate a massive increase 
in total body water (TBW) In contrast, studies lasting over a year fail to show such overt increase No 
explanation for this difference between long- and short-term studies can be found in literature 
Therefore, we analysed our 3 years data with respect to changes in TBW during rhGH treatment and 
evaluated possible gender differences In the analysis 24 women (age 36 3±12 7 year) and 20 men 
(age 37 5±13 1 year) with a complete data set were included All patients suffered from growth 
hormone deficiency and were studied every 6 months up to 3 years, with two additional visits the first 
year Treatment goal was to achieve a IGF-I level within 2 standard deviations of the control 
population (age corrected) 
During rhGH treatment body weight remained stable the first 6 months after which a steady increase 
m body weight was seen (p=0 05) considering men and women together TBW showed a steep rise 
(2L) the first 3 months of treatment followed by a plateau and again an increase from 12 months on 
(p=0 032) A similar pattern was seen in men and women separately with more pronounced effects in 
men Percentage TBW showed a robust increase (3%) in the first 3 months of treatment (p<0 001), 
plateaued till 12 months and decreased thereafter (p=0 033) to values at about 1 5% above baseline 
(p=NS to baseline) TBW responsivity (ATBW (L)/rhGH dose (IU/day/kg)) increased during the first 3 
months of treatment (p<0 001), then decreased with a nadir at 6 months (p=0 033) and again 
gradually increased till the end of the analysis A similar even more pronounced response was 
observed in men alone In the first year of treatment statistically significant correlations could be 
demonstrated between all parameters (GH, AIGF-I, ATBW, A%TBW) In the later phases only the 
correlation between IGF-I and TBW reached statistical significance 
From the data in the present study it appears that rhGH substitution has a dual effect on body water 
Initially there is a steep increase in TBW, which can be fully explained by changes in %TBW, and is 
not accompanied by changes in body weight In the second phase TBW steadily increases with a 
concomitant nse m body weight and a decrease / plateauing of %TBW In the initial phases of rhGH 
therapy GH dose is directly related to the changes in IGF-I Together the data suggest that in the first 
phase the increases in total body water can fully be explained by changes in %TBW reportedly 
mediated by changes in the renin-angiotensm-aldosterone system, the atrial natriuretic factor factor 
and prostaglandins These changes are more pronounced m men than in women, probably due to a 
higher GH sensitivity in the former In the second phase the increase in TBW which is accompanied by 
an increase in body weight but a stable %TBW is correlated with changes in IGF I only and not with 
the GH dose, In this phase the anabolic effect of IGF-I may prevail 
Introduction 
Soon after the introduction of GH therapy 
in children in 1957, it appeared that GH 
administration not only influenced skeletal 
growth, but also had significant effects on 
body composition (1,2) 
Some short-term studies in GH deficient 
adults treated with fixed GH dose reported 
a tremendous increase (up to 3.5 L) in total 
body water (TBW) during the first months 
of replacement therapy (3,4,5) Till now 
only few long-term studies addressing the 
fate of TBW during GH treatment in GH 
deficient adults have been published 
(6,7,8) The substantial increase in TBW 
seen in short-term studies was not reported 
in studies lasting over 1 year Apparently 
TBW rapidly increases after the 
(re)introduction of GH and reaches its 
maximum after six months, after which a 
decrease is seen. The initial changes m 
TBW are attributed, among others, to GH 
mediated activation of the renin-
52 
angiotensin-aldosterone system (RAAS) 
system (9). Although many studies address 
the effects of GH replacement in GH 
deficient adults on the changes m total 
body water (TBW), none evaluated 
possible gender differences and only few 
short-term studies (9,10) try to give an 
explanation of the changes in TBW found. 
Given the known differences in GH 
sensitivity between men and women (12), 
with respect to IGF-I responsivity (11), and 
the reported changes in fat mass and fat-
free mass, we analysed our 3-years data 
with respect to the effects of GH treatment 
and subsequent IGF-I changes on the 
changes in TBW. We will postulate a 
hypothesis based on the observed pattern 
of changes of TBW. 
Subjects and methods 
Patients 
Forty-four patients (24 women, age 36.3 ± 
12.7 years; 20 men, age 37.5 ± 13 1 years 
(mean±SD)) suffering from growth 
hormone deficiency, were included in this 
analysis. Growth hormone deficiency was 
diagnosed, when patients were known with 
hypothalanuc-pituitary pathology or had 
been treated with GH in childhood and 
when an arginine test revealed a peak 
growth hormone concentration below 10 
mU/1 (13). Twenty women and 16 men 
received sex hormonal substitution 
therapy. All women were below the age of 
50 and none received transdermal estrogen 
substitution. Twelve men received 
parenteral androgen substitution, while 
only 2 had oral replacement therapy. None 
of the men had transdermal substitution. 
Eight patients (1 pre-menopausal women 
and 7 men) were eugonadal. Thirty-five 
patients received corticosteroid 
replacement therapy. Forty-two patients 
needed thyroid hormone substitution. 
Pituitary pathology was idiopathic in 11 
patients. In the remaining 33 patients GH 
deficiency was caused by a pituitary 
adenoma in 12 patients, 
craniopharyngioma in 7 patients. 
congenital lesions in 5, other intracranial 
tumors in 4 (meningioma, epiphannx 
carcinoma, germinoma, 
rhabdomyosarcoma, medulloblastoma), 
Sheehan's disease in 2, and empty sella, 
meningitis and trauma each in one patient. 
Most (N=28) patients had been treated 
surgically. Eleven patients received 
radiotherapy 2 to 26 years before the start 
of rhGH substitution Duration of growth 
hormone deficiency varied from 1 to 36 
years All patients signed an informed 
consent to the protocol, which was 
approved by the University Hospital 
Ethical Committee. 
Patients were treated with rhGH 
(Genotropin®, Pharmacia-Upjohn or 
Humatrope , Eli Lilly) in varying doses. 
The treatment goal was to achieve an IGF-I 
concentration within the age corrected 
normal range (mean ± 2SD) for our 
laboratory (14) Patients started all with 1 
IU/day and the rhGH dose was adjusted 
each visit if necessary. The visits were 
monthly during the first 6 months and 
twice a year thereafter Data up to 36 
months were included in this analysis 
Serum IGF-I concentration and TBW and 
%TBW were measured every 6 months 
Serum IGF-I was determined by 
radioimmunoassay as described before 
(13) Body composition parameters were 
measured using bio-impedance analysis 
using the Akem 101 device The electrodes 
were placed as described by Lukaski (15). 
Apparatus specific conversions as 
delivered by the company were used. Inter-
assay coefficient of variation was 3.3% 
TBW responsivity was defined as 
ATBW(L) 
rhGHdose(IU I day I kg) ' 
Statistical methods 
Data are given as mean ± SEM, except for 
age where mean ± SD is used. For the 
assessment of the time effect or the within-
subject time*gender effect a repeated 
measures analysis of vanance was used 
(significance denoted by p). This was 
possible as all patients had a complete data 
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set. Correlations between GH dose, AIGF-
I, ATBW and A%TBW were calculated 
using Pearsons' correlation coefficient 
(significance denoted by p*). Comparison 
of baseline characteristics between men 
and women was performed using a two 
sample Student T-test (significance 
denoted as p**). Statistics were calculated 
using SPSS 9.0 for windows. 
Results 
Baseline weight, TBW, %TBW and 
IGF-I values 
Baseline weight did not differ significantly 
between both genders at the start of the GH 
therapy (women 72.3 ±2 .5 kg vs. men 
77.5 ± 2.9 kg; p**=NS). The mean TBW 
(31.7+0.7 vs. 41.8 ± 1.2 L) was 
significantly lower in women than in men 
(p**<0.01). Thus, percentage TBW was 
higher in men than in women (54.5 ± 0.9 
and 45.6 ± 0.6, respectively, p**<0.01). 
Baseline serum IGF-I level (8.7 ± 0.7 vs. 
11.7 ± 0.9 nmol/1) was significantly lower 
in women than in men (p**<0.05). 
Baseline IGF-I SDS was -1.9 ± 0.9 for 
women and -1.4 ± 0.8 for men (p**=NS). 
Effects of rhGH on body weight, TBW 
and %TBW 
ABody weight 
Body weight of women and men together 
showed a slight increase after 3 months of 
rhGH therapy followed by a decrease with 
a nadir after 6 months of treatment. 
however, none of these changes reached 
statistical significance (fig 1). From 12 
months on, however, a gradual increase in 
body weight was observed up till 3 years 
(p=0.05). 
Considering women and men separately, 
during the first 12 months no statistically 
significant changes in body weight (fig 2) 
were observed during rhGH therapy 
neither in women nor in men (p=NS). 
From 12 months on weight tended to 
increase in both women (p<0.10) and men 
(P=NS). 
ATBW 
Considering the population of women and 
men together, 3 months after the 
introduction of rhGH a steep increase in 
TBW of about 2 L (fig 1) was observed 
(p<0.001). This increase was followed by a 
plateau from 3 to 12 months. From 12 
months on there was a steady increase in 
TBW until the end of the study at 36 
months (p=0.032). Considering women 
and men separately, rhGH replacement 
induced an initial increase in TBW in both 
genders (p<0.001), reaching its maximum 
after 3 months. Between 3 and 12 months 
TBW stabilised or slightly decreased in 
women and men. Again, from 12 months 
on TBW gradually increased in both 
women and men, although not statistically 
significant (fig 2). The increments in 
TBW, however, were more pronounced in 
men than in women (p=0.010) at all time 
intervals form 24 months on. 
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Considering women and men together, 
percentage TBW increased to about 3% 
during the first 3 months of rhGH 
treatment (p<0.001). This was followed by 
a plateau from 3 to 12 months after which 
a decrease was seen with a nadir at 18 
months (p=0.033). Between 18 and 36 
months the %TBW plateaued at about 
1.5% above baseline (p=NS versus 
baseline) (fig 1). 
In women %TBW increased the first 3 
months of treatment (p<0.001), after which 
a steady decrease was seen (from 3 to 36 
months: p=0.039). In men %TBW initially 
increased with its maximum after 3 months 
(p<0.001). Thereafter a decrease was 
observed followed by a plateau (fig 2). 
Responsivity of TBW related to the 
weight corrected rhGH dose 
TBW responsivity 
In the overall population of women and 
men TBW responsivity, i.e. ATBW 
(L)/rhGH dose (IU/day/kg) increased, 
reaching its maximum at 3 months 
(p<0.001), thereafter responsivity 
statistically significant decreased reaching 
a nadir at 6 months (p=0.033), after which 
a gradual increase was observed again until 
the end of the study (p<0.001, fig 3). 
Considering women and men separately, in 
both men and women TBW responsivity 
showed the same biphasic time pattern as 
in the overall group, however, changes 
from 6 months on tended to be statistically 
significant (p=0.08) only in men, not in 
women (fig 3). From 12 months on at all 
time intervals TBW responsivity was more 
pronounced in men than in women 
(p<0.05) 
Correlations between GH dose, AIGF-I, 
ATBWandA%TBW 
During the first 12 months of treatment 
there was a statistically significant 
correlation between the GH dose used for 
substitution and AIGF-I (r=+0.638; 
p*<0.01), ATBW (r=+0.483; p*<0.01), 
andA%TBW (r=+0.483; p*<0.01, 
respectively). During this initial period 
there were also statistically significant 
correlations between AIGF-I and both 
ATBW (r=+0.485; p*<0.01) and A%TBW 
(r=+0.599; p*<0.01). After 12 months of 
treatment no further statistical significant 
correlations between the GH dose and 
either ATBW (r=-0.027; p*=NS) or 
A%TBW (r=-0.050; p*=NS) could be 
demonstrated. The only statistical 
significant correlation persisting after 12 
months of treatment was between AIGF-I 
and ATBW (r=+0.365; p*<0.01). No 
significant correlation between AIGF-I and 
A%TBW could be demonstrated 
(r=+0.184,p=NS). 
Discussion 
The present study shows that rhGH 
treatment of GH deficient men and women 
induces an initial increase in TBW during 
the first 3 months of therapy. This is in line 
with literature data indicating sodium and 
water retention during the initial months of 
treatment (3,4,5,10). In our study, 
however, this increase in TBW is followed 
by a plateau between 3 and 12 months of 
treatment. From 12 months on TBW again 
significantly increases up till the end of the 
study period at 36 months. TBW 
responsivity i.e. ATBW per IU GH 
administered per kg body weight per day, 
showed a similar even more distinct 
biphasic response pattern, which was, 
however, more pronounced in men than in 
women, probably due to the higher GH 
responsivity in the former (11,13). 
Scrutinising literature data 
(3,6,7,8,10,16,17,18) a comparable TBW 
response pattern could be derived, i.e. a 
rapid increase in TBW is followed by a 
decrease and finally again by an increase. 
In these studies, however, much higher, 
fixed GH dosages than in the present study 
were used, which resulted in a more 
pronounced initial increase in TBW (about 
7%) and a more prominent decrease 
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Figure 3 Effects ofGH replacement on TBW responsivity for all 
44 patients with GH deficiency included and for women and men 
separately 
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thereafter (from 7 to 4%) In these studies 
the changes in TBW were measured using 
vanous techniques, ie ΒΙΑ (10,18), 
82bromide dilution (10), total body 
potassium measurement (3, 8), deutenum 
dilution (5), or dual energy x-ray 
absorptiometry (6,7) In all cases the 
changes exceeded the intern error of the 
used measurement by far, therefore we feel 
confident that the biphasic changes in 
TBW observed in our analysis are not due 
to the use of ΒΙΑ method, but are a true 
reflection of the events in the body due to 
GH replacement 
Unlike TBW, body weight did not change 
significantly during the first 12 months of 
treatment From 12 months on, however, 
body weight tended to increase in the 
overall group This is in line with literature 
data (19,20) 
Considering the changes in %TBW, 
initially, a steep increase is seen followed 
by a decrease From 18 months on the 
%TBW reached a plateau at about 1 5% 
above baseline No literature data dealing 
with %TBW changes over periods longer 
than 1 year are available Only in a recent 
paper M0ller et al (9) observed, that adult 
patients with GH deficiency who initially 
had a slightly lower TBW as compared to 
healthy subjects, accumulated water after 
GH substitution The authors argued that 
this water accumulation indicated a change 
towards the physiological hydration state 
This hypothesis is consistent with our data 
during the first 12 months of treatment In 
the first 12 months penod, M0ller and we 
observed an overshoot response of TBW, 
with M0ller observing an increase up to 
7% (10), whereas in the physiological state 
an increase of about 2% would be 
sufficient for a physiological hydration 
state 
From the data in the present study it 
appears that GH substitution therapy has a 
dual effect on total body water Initially 
there is a nse in TBW, which can fully be 
explained by the changes in %TBW This 
phase is evanescent and accompanied by 
an unchanged body weight In the second 
phase TBW steadily increases with a 
concomitant increase in body weight and a 
decrease in or plateauing of %TBW 
Considering the changes in TBW and 
%TBW in relation to the GH dose and to 
IGF-I it appears that in the initial stages of 
GH therapy the GH doses are directly 
correlated with the changes in IGF-I, TBW 
and %TBW After 12 months of treatment, 
however, only the change in TBW - not in 
%TBW - statistically significantly 
correlated to the changes in IGF-I, not to 
the dose of GH 
Analysing the data from women and men 
separately showed that the dual action of 
GH on water distribution could be found in 
men, but not in women Although in the 
initial phase no statistical significant 
differences can be demonstrated between 
women and men in the second phase the 
differences for ATBW, and TBW 
responsiveness reach statistical 
significance These differences can be 
ascribed to the higher GH sensitivity in the 
former (11,13) Together, these data are 
indicative of GH effects mediated through 
different effector systems In the first phase 
the increase in TBW is fully explainable by 
changes in %TBW and probably mediated 
by GH induced changes in RAAS, ANF or 
prostaglandins (9) These changes in TBW 
are more pronounced in men while our 
data do not indicate a dual action in 
women In the second phase the increase in 
TBW is accompanied by an increase in 
body weight, but a stable %TBW In this 
phase TBW changes correlated only to the 
changes in IGF-I per se and not to the GH 
dose This may be indicative of an anabolic 
effect in the second phase of rhGH 
treatment knowingly being exerted by IGF-
I These data stress the dual time related 
action of GH on body fluid distribution in 
GH deficient adults 
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Chapter 6 
CPMP recommendations on diagnosis and treatment of adults with 
growth hormone deficiency 
Author J. Span 
(Adopted by CPMP may 2000) 
Introduction 
A letter from the Council of the 
International Growth Hormone Society 
(see appendix) informed the CPMP of 
inconsistencies between GRS guidelines 
and the current European SPC text with 
respect to both diagnosing criteria and 
dosing of adult patients with growth 
hormone deficiency. In this letter Prof. 
Christiansen on behalf of the GRS council 
states that the GRS guideline - published 
in JCEM 1998;83:379-381 - is now 
accepted by a number of regulatory 
authorities among which the FDA and 
ARA. Because the (effectual) differences 
between the EMEA opinion - formulated 
in Berlin 1995 - and the GRS are minor the 
GRS Council wonders if the GRS 
guideline can be incorporated in the 
European SmPC. 
European SmPC text 
Only patients with a severe growth 
hormone deficiency should be treated. 
Severe growth hormone deficiency is 
defined as reduced or absent growth 
hormone response to two dynamic tests. 
Only patients with known hypothalamic-
pituitary pathology and deficiency of at 
least one pituitary hormone (being not 
prolactin) or patients with childhood onset 
of growth hormone deficiency should be 
tested. 
Comments 
Diagnosis 
The European summary of product 
characteristics (SPC) text and the GRS 
guideline consider only pre-selected 
patients appropriate for respectively two or 
one test(s). The (assumed) low sensitivity 
(80% at best) and specificity (70% at best) 
of all known stimulation tests will - in the 
GRS setting - bears the risk to a over-
diagnosing of patients with growth 
hormone deficiency (this is in contrast to 
the conclusion of the GRS council). 
Because it can be expected that almost all 
patients pre-selected have a growth 
hormone deficiency (personal experience) 
a second test as required under the 
European guideline will give only limited 
information. It is questionable if the 
increased inconvenience of a second 
dynamic test is outweighed by the extra 
information gained. In case the GRS 
guideline on this point is incorporated in 
the European guideline, this will have no 
practical influence on the accuracy with 
which adults are diagnosed but reduce the 
inconvenience to the patients. 
In patients with childhood onset of growth 
hormone deficiency a retesting is required 
under both the European and the GRS 
guideline. In case these patients have a 
hypothalamic-pituitary pathology and 
deficiency of at least one pituitary 
hormone (being not prolactin) this seems 
logic. However, in patients diagnosed in 
childhood with partial growth hormone 
deficiency the need of growth hormone 
substitution in adulthood remains 
questionable. Using only one test - as 
advocated by the GRS - bears the risk of 
over-diagnosing growth hormone 
deficiency in this population of patients. 
Two tests, as required by the European 
guideline, seems a better alternative 
although no scientific proof for this way of 
working exists. An alternative is to test 
patients only in case the IGF-I is below 2 
SDS of the age corrected mean. 
Measurement of IGF-I concentration is an 
accepted diagnostic tool in children and 
young adults (up to the age of 20 years) 
with a reasonable sensitivity and 
specificity. One test seems appropriate in 
this group of patients with low IGF-I and 
the information gained with a second test 
will be very limited. Maybe the GRS 
should be suggested to adapt the European 
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vision to this population into their 
guideline. 
The GRS advocates the use of the ΓΤΤ as 
the best test available. No scientific 
evidence of the superiority of ΠΤ over a 
number of other tests (e.g. arginine, 
GHRH, arginine + GHRH) exists. At best 
can be stated that the experience with ΠΤ 
is worldwide the greatest, while of the 
alternative tests - as in the ΠΤ - the 
accuracy in adults remains to be proven. 
The cut-off point that demonstrates growth 
hormone deficiency is set at 3 μg/L. This 
can be considered a strict rule and is surely 
an item that can be added to the European 
guideline. 
Treatment 
The GRS guideline advises to start with a 
dose of 0.45-0.90 IU/day. The European 
guideline gives the possibility to start with 
a dose 0.018 IU/kg/day that is for a patient 
of 100 kg a dose of 2 IU/day. In order to 
reduce the acute adverse events due to 
fluid retention the GRS advised starting 
dose is considered to be more appropriate. 
Both guidelines advise to monitor the 
treatment efficacy using IGF-I 
concentration. None of the guidelines gives 
an advice in case a patient is identified 
according to the definitions given in the 
respective guidelines but has a normal 
IGF-I. An advice for monitoring patients 
with normal IGF-I values at start should be 
added to the guidelines. 
Recent publications show that the mean 
dose needed for men are much lower (1.5 
IU/day) than for women (2.5 IU/day), with 
men showing an increasing IGF-I 
sensitivity over time. This suggest that 
women, especially those on oral oestrogen 
replacement, are at risk to be under-treated 
while men are at risk to be over-treated. 
The increasing sensitivity to growth 
hormone (expressed as change in IGF-I per 
growth hormone dose) in men makes the 
risk of over-treatment in time more serious. 
These newly gained insights in growth 
hormone treatment should be incorporated 
in both guidelines 
Safety issues 
Safety issues will not be discussed here 
because a consensus guideline will be 
under-taken in Virginia 9-11 may this year. 
Conclusion 
Both guidelines can be optimised using the 
newest insights in growth hormone 
treatment in adults. The European 
guideline is very strict for those acquiring 
growth hormone deficiency in adulthood 
and the less inconvenient approach as 
advocated by the GRS seems as effective. 
For young adults diagnosed with "partial" 
growth hormone deficiency in childhood a 
more stringent approach seems reasonable 
and for this subgroup of patients the 
European guideline seems more 
appropriate. Suggested is to include a low 
IGF-I concentration into the requirement 
for young adults formerly diagnosed with 
"partial" growth hormone deficiency and 
then perform only one dynamic test. 
The starting treatment dose advice by the 
European guideline can be to high and it is 
suggested to adopt the GRS position on 
this point. The newest data show that men 
are in lesser need of growth hormone than 
women are in order to reach the treatment 
goal, men showing an increasing, 
sensitivity to growth hormone and thus an 
ongoing correction of the used growth 
hormone dose. This should be added to 
both guidelines. 
Recommendations 
1 For patients with adulthood onset of 
growth hormone deficiency the GRS 
guideline can be adopted. 
2 For patients with a diagnosis of 
"partial" growth hormone deficiency 
in childhood, low IGF-I (<2SDS) 
concentrations should be included as a 
selection criterion. One test seems 
appropriate in young adults previously 
treated with growth hormone and low 
IGF-I concentrations. 
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3 The cut-off point of a test should be 
very strict, the suggested cut-off point 
of 3 μg/l can be considered a strict rule 
and is surly an item that can be added 
to the European guideline. 
4 The starting dose as advised in the 
European SmPC text (0.018 
IU/kg/day) can be to high. 
Recommended is to adopt the starting 
dose of the GRS. 
5 Guidance for patients with normal 
IGF-I should be added. 
6 It should be mentioned that women, 
especially those on oral oestrogen 
replacement, need higher doses growth 
hormone (mean 2.5 IU/day) than men 
(mean 1.5 IU/day). 
7 In men, during GH treatment, there is 
an increasing sensitivity to growth 
hormone which introduces the risk of 
over treatment in time. 
Proposal (adult growth hormone 
deficiency only) 
4.1 indications 
Adults:Growth hormone is indicated for 
replacement therapy in adults with 
pronounced growth hormone deficiency. 
Patients with severe growth hormone 
deficiency in adulthood are defined as 
patients with known hypothalamic-
pituitary pathology and at least one known 
deficiency of a pituitary hormone not being 
prolactin. Only these patients should 
undergo a dynamic test in order to 
diagnose or exclude a growth deficiency. 
Patients with childhood onset growth 
hormone deficiency not meeting the above 
criteria must have a low IGF-I (<2SDS) in 
order to be considered for a dynamic test. 
The cut-off point of the dynamic test 
should be strict (peak growth hormone 
concentration < 3 μg/L). 
4.2 Posology 
The recommended starting dose is 0.45 -
0.90 IU/day. This dose should be gradually 
increased according to individual patient 
requirements as determined by the IGF-I 
concentration. Treatment goal should be 
IGF-I concentrations within 2 SDS from 
the age corrected mean. Patients with 
normal IGF-I concentrations at the start of 
treatment should be administered growth 
hormone up to an IGF-I level in to upper 
range of normal, not exceeding the 2 SDS. 
In order to reach the defined treatment goal 
men need much lower growth hormone 
(approximately 1.5 IU/day) than women 
(approximately 2.5 IU/day), with men 
showing an increasing IGF-I sensitivity 
over time. This means that there is a risk 
that women, especially those on oral 
oestrogen replacement, are under-treated 
while men are over-treated. The increasing 
sensitivity to growth hormone (expressed 
as change in IGF-I per growth hormone 
dose) over time in men makes the risk of 
over-treatment more serious. The accuracy 
of the growth hormone dose should 
therefore be controlled ever 6 months. 
In cases of persistent signs and symptoms 
of fluid retention the growth hormone dose 
should be decreased. 
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Summary 
In this thesis an overview of the syndrome of adult growth hormone deficiency is given 
together with a description of the effects of growth hormone substitution in patients with 
growth hormone deficiency The second target of this thesis is to explore the differences 
between the genders 
In chapter 1 we gave an overview of the syndrome of adult growth hormone deficiency 
The syndrome includes, among others, detenorated quality of life, changes in body 
composition, reduced strength and exercise capacity, reduced bone mineral content, changes 
in cardiac function, renal perfusion, immune system and metabolic homeostasis Although 
both men and women display the same signs and symptoms, the syndrome is more explicit in 
women with greater changes in body composition parameters and bone mass 
The diagnosis of growth hormone deficiency in adults is based upon the clinical picture, 
biochemical markers, a possible aetiology and a provocation test In practice, patients who 
have either the clinical picture of growth hormone deficiency and/or hypothalamic-pituitary 
pathology - one or both preferably combined with a low insulin like growth factor-I (IGF-I) 
level - will be subjected to a provocation test Provocation tests of choice are the insulin 
tolerance test or the arginine test or the combined arginine plus growth hormone releasing 
hormone test all with their test and laboratory specific cut-off points 
In chapter 2 we demonstrated that IGF-I concentrations could be used in the diagnosis of 
growth hormone deficiency in adults Under the age of 40 years measuring plasma IGF-I 
provides a useful tool to diagnose growth hormone deficiency In these patients growth 
hormone deficiency can be assumed provided that other causes for IGF-I disturbance are 
excluded Above the age of 40 years of age plasma IGF-I values exceeding 15 nmol/1 virtually 
exclude growth hormone deficiency 
In chapter 3 we showed that during growth hormone (GH) substitution therapy IGF-I level 
increases but for comparable changes women need more growth hormone than men, 
especially those women on oestrogen replacement therapy Over time it becomes evident that 
men need a decreasing amount of growth hormone in order to achieve the same IGF-I level 
The clinical importance of these findings is that with time women are prone to under-
treatment, while men have the nsk of over-treatment 
In chapter 4 we demonstrated that gender bom differences in IGF-I responsivities to 
recombinant human growth hormone are accompanied by gender differences in (the extent of) 
body composition changes to recombinant human growth hormone Probably due to these 
gender differences in IGF-I responsivity the increases of total body water and fat free mass to 
recombinant human growth hormone replacement were more pronounced in men than in 
women Remarkably, however, in men only total body water and fat free mass responses 
relative to AIGF-I increased during the 2 years of recombinant human growth hormone 
therapy To our opimon this phenomenon might be explained, among others, by increasing 
target organ sensitivity to IGF-I over time in men, however, not in women The effect on fat 
mass could not be related to the changes in IGF-I, suggesting a direct effect of growth 
hormone on fat mass 
In chapter 5 evaluation of our 3 year data on total body water showed that the changes in 
total body water follow a biphasic pattern, starting with an steep increase in total body water 
overshooting the necessary correction of the dehydration known from the syndrome This 
phase is probably growth hormone dependent and probably mediated by the remn-
angiotensin-aldosterone system pathway, the atrial natriuretic factor and /or prostaglandins 
During the second phase the increase of total body water is associated with an increase in lean 
body mass and correlated to changes in IGF-I This suggests that in the second phase the 
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anabolic effects of growth hormone/IGF-I are prominent. This biphasic pattern can offer an 
explanation for the side effects associated with growth hormone replacement and their 
recession after some months of treatment. 
Chapter 6 showed the European guideline on diagnosis and treatment of growth hormone 
deficiency in adults. This document is based on the Consensus paper of the Growth Hormone 
research Society. The adjustments made, however, are fully based on the results described in 
this thesis. 
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Samenvatting 
In dit proefschrift wordt een overzicht gegeven van het syndroom van groeihormoon (GH)-
deficiëntie bij volwassenen. Naast een beschrijving van het syndroom worden ook de effecten 
van GH substitutie beschreven. Een tweede doel van dit proefschrift is het beschrijven van de 
verschillen tussen mannen en vrouwen, vooral met betrekking tot de effecten van de 
substitutie. 
Hoofdstuk 1 geeft een overzicht van het syndroom van GH-deficiëntie op volwassen leeftijd. 
Het syndroom omvat onder andere verslechtering van de kwaliteit van leven, veranderingen in 
de lichaamssamenstelling, verminderde spierkracht en uithoudingsvermogen, een verminderd 
botmineraal-gehalte, verslechtering van de hartfunctie, verminderde nierdoorbloeding, 
veranderingen in het immuunsysteem en verstoringen van de metabole homeostase in het 
lichaam. Hoewel mannen en vrouwen dezelfde afwijkingen en klachten presenteren is het 
syndroom bij vrouwen meer uitgesproken dan bij mannen. Met name de veranderingen in 
lichaamssamenstelling en botmassa zijn meer uitgesproken bij vrouwen. 
De diagnostiek van een GH deficiëntie bij volwassen patiënten is gebaseerd op het klinisch 
beeld, specifieke biochemische parameters en provocatie testen. In de praktijk zal bij een 
patiënt die het klinisch beeld van groeihormoondeficiëntie toont en/of een hypothalame dan 
wel een hypofysaire afwijking heeft en/of een laag IGF-I gehalte, een provocatie test worden 
uitgevoerd. Provocatie testen zijn bij voorkeur een insuline tolerantie test of een arginine test 
of een gecombineerde arginine + GHRH belastingstest waarbij de diagnostische grenzen test-
en ziekenhuisspecifiek zijn. 
In hoofdstuk 2 toonden we aan dat de plasma IGF-I spiegel een rol kan spelen bij de 
diagnostiek van GH-deficiëntie bij volwassenen. Onder het 40s,e jaar kan bepaling van de 
IGF-I spiegel een nuttig hulpmiddel zijn bij de diagnostiek van GH-deficiëntie. Bij deze 
patiënten kan GH-deficiëntie worden aangenomen als de IGF-I spiegel lager dan 15 nmol/1 is, 
mits andere oorzaken voor een verlaagde IGF-I spiegel zijn uitgesloten. Boven het 40ste jaar 
sluit een IGF-I spiegel van meer dan 15 nmol/1 een GH-deficiëntie uit. 
In hoofdstuk 3 toonden we aan dat na GH-substitutie de IGF-I spiegel stijgt, maar dat 
vrouwen voor dezelfde veranderingen meer GH nodig hebben dan mannen. Vrouwen die met 
oestrogenen worden gesuppleerd dan wel orale anticonceptiva gebruiken, hebben meer GH 
nodig dan vrouwen zonder oestrogenen behandeling. In de loop van de tijd blijken mannen 
zelfs minder GH nodig te hebben om een zelfde substitutie-niveau als voorheen te behalen. 
De klinisch relevante consequentie van deze bevindingen is dat bij vrouwen gewaakt dient te 
worden voor onderbehandeling, terwijl bij mannen overbehandeling dreigt zeker na enige tijd. 
In hoofdstuk 4 hebben we aangetoond dat de geslachtsverschillen gezien in het antwoord van 
IGF-I op GH-toediening worden vergezeld van geslachtsverschillen in het effect op de 
lichaamssamenstelling. Ten gevolge van de geconstateerde verschillen in de IGF-I response 
zien we ook dat de toename van totaal lichaamswater en vet vrije massa bij mannen meer 
uitgesproken is dan bij vrouwen. Opmerkelijk is dat, alleen bij mannen, de veranderingen in 
het totaal lichaamswater en de vetvrije massa gerelateerd zijn aan de veranderingen in de IGF-
I gedurende de twee jaar van de analyse. Een mogelijke verklaring voor deze waarnemingen 
kan zijn, dat althans bij mannen de eindorganen een toenemende gevoeligheid voor 
groeihormoon ontwikkelen in de loop van de tijd. Een andere opmerkelijke waarneming in 
deze studie is dat de veranderingen in de vetmassa niet gerelateerd zijn aan de veranderingen 
in de IGF-I spiegels, hetgeen zou verklaard kunnen worden door een direct, dus niet IGF-I 
gemedieerd, effect van GH op het vetmetabolisme. 
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In hoofdstuk 5 hebben we onze 3 jaars gegevens met betrekking tot totaal lichaamswater 
geanalyseerd. Deze analyse liet een bifasisch verloop in the veranderingen van het totaal 
lichaamswater zien. Na de start van de GH substitutie neemt de hoeveelheid water, in 
voordien enigszins ondervulde patiënten, sterk toe en is er sprake van een "overshoot" reactie. 
Hierna herstelt de waterhuishouding zich tot een niveau dat ook gezien wordt bij gezonde 
controles. Na deze fase neemt de totale hoeveelheid lichaamswater echter opnieuw gestaag 
toe. De eerste fase is GH-afhankelijk en mogelijk gemedieerd door GH-geïnduceerde 
veranderingen in het renine-angiotensine-aldosteron-systeem, de atriaal natriuretische factor 
en/of Prostaglandines. De tweede fase is geassocieerd met veranderingen in IGF-I spiegel en 
een toename in de vetvrije massa. Het lijkt erop dat in deze fase het anabole effect van 
GH/IGF-I de overhand heeft. Dit bifasisch verloop zou een verklaring kunnen bieden voor de 
bijwerkingen die worden gezien in het begin van de behandeling en voor het verdwijnen van 
deze bijwerkingen in een latere fase. 
Hoofdstuk 6 laat de tekst van de Europese richtlijn met betrekking tot de diagnose en 
behandeling van volwassenen met een GH deficiëntie zien. Aan deze tekst ligt de richtlijn van 
de "Growth hormone Research Society" ten grondslag met aanpassingen welke zijn gebaseerd 
op de resultaten van het bovengemelde onderzoek. 
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Dankwoord 
Dit boekje is tot stand gekomen met de hulp van velen. Zonder de ongenoemden tekort te 
willen doe wil ik enkelen met name noemen: 
Mijn promotor die steeds maar weer het door mij aangeleverde van begin tot het eind doorlas 
en er nog al eens dezelfde fouten uithaalde. Prof dr. Smals was in staat dit te doen zonder 
kwaad te worden of zelfs maar geïrriteerd. Wel stond ik bij tijd en wijlen bloot aan stekende 
humor. Hij heeft mij geleerd dat de verwoording van de boodschap minstens even belangrijk 
is als de boodschap zelf. 
Mijn co-promotor Dr Pieters, met wie discussies tot een minimum van tijd werden beperkt. 
Argumenten werden één keer genoemd, gewogen en al dan niet verworpen, kritieken waren 
duidelijk en to the point. Gerlach beperkte zich vaak tot de inhoud van het geschrevene en niet 
tot het geschrevene zelf. Hij heeft me ook het relatieve van de wetenschap laten zien. 
Prof. Dr. Kloppenborg, de man die mij in 1984 kennis liet maken met "De Endocrinologie", 
waaraan ik sindsdien mijn hart heb verloren, leerde ik nog beter kennen als de hoogleraar die 
graag wat tegenspel had (en dat van mij dan ook in (te) ruime mate kreeg). 
Dr. Koopmans, Peter als je me niet kwaad had gemaakt was ik er nooit aan begonnen. 
Dr CGJ Sweep, hoofd van de afdeling Chemische Endocrinologie, zonder wiens hulp dit 
proefschrift onmogelijk was geweest. 
Mijn ouders voor hun steun die ik altijd en onder alle omstandigheden heb mogen ontvangen, 
ondanks dat ze niet altijd geweten hebben wat ze aan het steunen waren. 
Conny, mijn vriendin die (gelukkig) ook mijn vrouw is, voor de mogelijkheid deze proeve te 
kunnen doen. Maar vooral omdat je hebt aangetoond (wetenschappelijk), dat er maar weinig 
is wat je gezamenlijk niet kunt bereiken. 
Bart, Guus en Femke voor het laten zien wat écht belangrijk is. "Bart gefeliciteerd, je had je 
diploma eerder dan ik". 
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Curriculum vitae 
In de koudste naoorlogse winter zag Jan op 19 januan 1963 te Waalwijk het levenslicht De 
eerste dagen van zijn leven zochten zijn ouders voor hem een evenwicht tussen verbranden - te 
dicht bij een hard gestookte kolenkachel - of bevnezen - te dicht bij de buitenlucht waar de 
temperatuur ver onder het nulpunt was Nadat het ijs in het doopvont gebroken kon worden 
werd hij op 16 februan gedoopt 
Na de kleuterschool waarvan hij na dne jaren (1969) afscheid nam, zette hij zijn opleiding voort 
op de St Aloysiusschool Daar kwamen al snel een aantal gebreken aan het licht Sprekend en 
denkend in het prachtige Brabantse dialect van "Wölk" (Waalwijk), gebeurde het ook wel eens 
dat dit dialect zijn dictees binnensloop Daarnaast waren er in dezelfde dictees vele - voor die 
tijd - raadselachtige en onbegrijpelijke fouten Een medisch onderzoek bracht geen duidelijke 
oorzaak voor deze fouten aan het licht Besloten werd dat Jan "gewoon" dom was 
Ruimtegebrek (ook toen al) op de lokale LOM school betekende echter, dat hij op de gewone 
lagere school zijn camere diende voort te zetten Een doublure in de derde klas was het gevolg 
Daarna bleef het aanmodderen tot de 6e klas, waar na een keuze voor het vervolg onderwijs 
gemaakt diende te worden In een poging zo hoog mogelijk te gnjpen en met gehinderd door 
enige kenms koos hij voor "HAVO" Deze keuze werd weliswaar ondersteund door gunstige 
testresultaten (CITO), maar hartgrondig tegengewerkt door de onderwijzer en hoofd van de 
lagere school Gesteund door zijn ouders kon hij zijn opleiding vervolgen aan de brugklas 
HAVO/VWO van het Dr Moller college te Waalwijk 
Na de brugklas ging Jan - tegen het advies van de conrector - naar het Gymnasium Nadat hij 
het leven, van met name de leraren Engels, Duits, Frans en Nederlands, moeilijk had gemaakt, 
staakte hij de klassieke opleiding na het behalen van het 4e jaar In het 5e jaar van het atheneum 
werd hij geplaagd door een te veel aan vnje tijd Een en ander had tot gevolg dat hij erg veel tijd 
in het sporten stak Hierin bereikte hij een niveau juist onder de nationale top 
Na het behalen van het VWO diploma, een aantal selecties en een loting bevond Jan zich in de 
situatie dat hij moest kiezen tussen een officiersopleiding bij de Kon Landmacht (logistieke 
dienst), of de studies Natuurkunde dan wel Medicijnen In eerste instantie werd gekozen voor 
Medicijnen Na enige tijd bleek deze studie sec onvoldoende uitdaging te bieden In januan 
1984 besluit hij op de afdeling Endocriene Ziekten (hoofd Prof Dr Kloppenborg) onderzoek 
naar de oestrogeen-receptor te vemchten Halverwege 1984 leert hij zijn huidige vrouw en 
vriendin (Conny) kennen Om de uitdaging van het studeren te sublimeren begint hij in 1985 de 
studie Informatica Dit is ook het laatste jaar dat hij sportief op nationaal m veau acteert De 
laatste wedstrijd is het Nederlands kampioenschap voor ploegen, een wedstrijd waann hij zijn 
persoonlijk record op het onderdeel 110 meter horden scherper stelt 
In 1986 sluit hij zijn doctoraal Geneeskunde (Nijmegen) af en begint hij de co-schappen Samen 
met zijn echtgenote wijdt hij zich aan de diagnostiek en behandeling van moeilijk behandelbare 
epilepsieen bij kinderen (onder leiding van Prof dr W Remer) De co-schappen gynaecologie en 
chirurgie trekken een dusdanige wissel op zijn fysieke gestel, dat de studie informatica na het 
behalen de propedeuse gestaakt moet worden 
In 1989 knjgt Jan zijn artsdiploma Hij is dan al enige tijd werkzaam als informaticus op de 
afdeling klinische neurofysiologie (KNF) van het Radboud ziekenhuis (nu UMC St Radboud) 
Deze positie verruilt hij m 1990 voor de "uitdagende" baan bij het College ter Beoordeling van 
Geneesmiddelen waar hij thans nog werkt 
Na een kortdurend onderzoek op het gebied van AIDS stapt hij in 1992 over op onderzoek naar 
de effecten van groeihormoon (afdeling Endocnene Ziekten, onder leiding van Prof dr 
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Kloppenborg, Prof dr Smals, Prof dr Heimus en Dr Pieters), een hormoon waarvan de ban thans 
nog niet gebroken is. 
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Definitions and abbreviations 
ALS 
ANF 
AO 
BF 
ΒΙΑ 
CI 
CO 
CPMP 
ECV 
ECW 
EMEA 
FDA 
FEV 
FFA 
FFM 
FM 
FVC 
GH 
GHIF 
GHR 
GHRH 
GHRH-R 
GHS 
GRS 
HDL-Cholesterol 
HypoCCS 
IGF 
IGFBP 
ICW 
IL 
1RS 
ΠΤ 
JAK 
KIMS 
L-DOPA 
LBM 
LDL-Cholesterol 
NK-cell 
PTH 
QoL 
RAAS 
SDS 
SEM 
SPC 
SS 
Acid Labile Substance 
Atrial Natriuretic Factor 
Adulthood Onset 
Body Fat 
Body Impedance Analysis 
Confidence intervals 
Childhood Onset 
Commity on Proprietary Medicinal Products 
Extra Cellular Volume 
Extra Cellular Water 
European Medicines Evaluation Agency 
Federal Drug and Food Administration 
Functional Expirating Volume 
Free Fatty Acids 
Fat Free Mass 
Fat Mass 
Forced Vital Capacity 
Growth Hormone 
Growth Hormone Inhibiting Factor 
Growth Hormone Receptor 
Growth Hormone Releasing Hormone 
Growth Hormone Releasing Hormone Receptor 
Growth Hormone Secretagogen 
Growth Hormone Research Society 
High Density Lipoprotein Cholesterol 
Hypopituitary Control and Complications Study 
Insulin-like Growth Factor 
Insulin-like Growth Factor Binding Protein 
Intra Cellular Water 
Interleukine 
Insulin Receptor Substrate 
Insulin Tolerance Test 
Janus Kinase 
Kabi International Metabolic Study 
Levo-Dopamin 
Lean Body Mass 
Low Density Lipoprotein Cholesterol 
Non-Killer cell 
Parathormone 
Quality of Life 
Renin-Angiotensin-Aldosterone System 
Standard deviation score; the figure gives the distance of an individual 
measure, expressed in standard deviations, from the mean for a given 
group. Using SDS it is possible to compare effects of an active 
substance in groups with different means but further equal effects. 
Standard Error of the Mean 
Summary of Product Characteristics 
Somatostatin 
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STAT Signal Transducers and Activators of Transcription 
TBK Total Body Potassium 
TBW Total Body Water 
TLC Total Long Capacity 
WHO World Health Organisation 
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Stellingen 
Meting van de plasma IGF-I concentratie is zinvol bij de diagnostiek van patiënten met 
groeihormoon-deficiëntie 
Na toediening van groeihormoon aan groeihormoon-deficiënte volwassenen bestaat er een 
verschil in het antwoord van IGF-I tussen mannen en vrouwen 
Na groeihormoon-substitutie zijn de veranderingen in lichaamssamenstelling bij mannen met 
groeihormoon-deficiëntie meer uitgesproken dan bij vrouwen 
Geslachtshormonen versterken de veranderingen in het IGF-I gehalte en de 
lichaamssamenstelling, gezien tijdens groeihormoon-substitutie 
Toediening van groeihormoon aan mannen met groeihormoon-deficiëntie heeft een bifasisch 
effect op de vochthuishouding 
Een éénmalige meting van groeihormoon is zinloos voor de diagnostiek van groeihormoon-
deficiëntie bij volwassenen 
Tomaten zijn onvruchtbaar zonder groeihormoon 
Door de toenemende inefficiëntie bij de NS knjgt de treinreizende promovendus meer tijd 
voor de voorbereiding van zijn promotie 
Het begeleiden van een promovendus met dyslexie is een met te onderschatten uitdaging voor 
zijn (co) promotor 
Ook al is een tablet acetylsahcylzuur van de voorzitter van het College ter Beoordeling van 
Geneesmiddelen afkomstig, dan nog is het geen veilig middel 
GrowthSpan is now available and is better than ever (GrowthSpan wordt aangeboden op 
internet voor "rejuvination" en bevat o a groeihormoon) 


